Trial watch

References

• Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 1973; 137:1142 - 62; http://dx.doi.org/10.1084/jem.137.5.1142; PMID: 4573839
   PubMed Web of Science ®Google Scholar
• Lanzavecchia A, Sallusto F, Ralph M. Ralph M. Steinman 1943-2011. Cell 2011; 147:1216 - 7; http://dx.doi.org/10.1016/j.cell.2011.11.040; PMID: 22263224
   PubMed Web of Science ®Google Scholar
• Nussenzweig MC, Mellman I. Ralph Steinman (1943-2011). Nature 2011; 478:460; http://dx.doi.org/10.1038/478460a; PMID: 22031432
   PubMed Web of Science ®Google Scholar
• Mellman I, Nussenzweig M. Retrospective. Ralph M. Steinman (1943-2011). Science 2011; 334:466; http://dx.doi.org/10.1126/science.1215136; PMID: 22034425
   PubMed Web of Science ®Google Scholar
• Banchereau J, Paczesny S, Blanco P, Bennett L, Pascual V, Fay J, et al. Dendritic cells: controllers of the immune system and a new promise for immunotherapy. Ann N Y Acad Sci 2003; 987:180 - 7; http://dx.doi.org/10.1111/j.1749-6632.2003.tb06047.x; PMID: 12727638
   PubMed Web of Science ®Google Scholar
• Klechevsky E, Flamar AL, Cao Y, Blanck JP, Liu M, O’Bar A, et al. Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR. Blood 2010; 116:1685 - 97; http://dx.doi.org/10.1182/blood-2010-01-264960; PMID: 20530286
   PubMed Web of Science ®Google Scholar
• Banchereau J, Schuler-Thurner B, Palucka AK, Schuler G. Dendritic cells as vectors for therapy. Cell 2001; 106:271 - 4; http://dx.doi.org/10.1016/S0092-8674(01)00448-2; PMID: 11509176
   PubMed Web of Science ®Google Scholar
• Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 2003; 19:225 - 34; http://dx.doi.org/10.1016/S1074-7613(03)00208-5; PMID: 12932356
   PubMed Web of Science ®Google Scholar
• Palucka AK, Ueno H, Fay JW, Banchereau J. Taming cancer by inducing immunity via dendritic cells. Immunol Rev 2007; 220:129 - 50; http://dx.doi.org/10.1111/j.1600-065X.2007.00575.x; PMID: 17979844
   PubMed Web of Science ®Google Scholar
• Ueno H, Klechevsky E, Morita R, Aspord C, Cao T, Matsui T, et al. Dendritic cell subsets in health and disease. Immunol Rev 2007; 219:118 - 42; http://dx.doi.org/10.1111/j.1600-065X.2007.00551.x; PMID: 17850486
   PubMed Web of Science ®Google Scholar
• Banchereau J, Pulendran B, Steinman R, Palucka K. Will the making of plasmacytoid dendritic cells in vitro help unravel their mysteries?. J Exp Med 2000; 192:F39 - 44; http://dx.doi.org/10.1084/jem.192.12.F39; PMID: 11120782
   PubMed Web of Science ®Google Scholar
• Berard F, Blanco P, Davoust J, Neidhart-Berard EM, Nouri-Shirazi M, Taquet N, et al. Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J Exp Med 2000; 192:1535 - 44; http://dx.doi.org/10.1084/jem.192.11.1535; PMID: 11104796
   PubMed Web of Science ®Google Scholar
• Li D, Romain G, Flamar AL, Duluc D, Dullaers M, Li XH, et al. Targeting self- and foreign antigens to dendritic cells via DC-ASGPR generates IL-10-producing suppressive CD4+ T cells. J Exp Med 2012; 209:109 - 21; http://dx.doi.org/10.1084/jem.20110399; PMID: 22213806
   PubMed Web of Science ®Google Scholar
• Jotwani R, Palucka AK, Al-Quotub M, Nouri-Shirazi M, Kim J, Bell D, et al. Mature dendritic cells infiltrate the T cell-rich region of oral mucosa in chronic periodontitis: in situ, in vivo, and in vitro studies. J Immunol 2001; 167:4693 - 700; PMID: 11591800
   PubMed Web of Science ®Google Scholar
• Matsui T, Connolly JE, Michnevitz M, Chaussabel D, Yu CI, Glaser C, et al. CD2 distinguishes two subsets of human plasmacytoid dendritic cells with distinct phenotype and functions. J Immunol 2009; 182:6815 - 23; http://dx.doi.org/10.4049/jimmunol.0802008; PMID: 19454677
   PubMed Web of Science ®Google Scholar
• Nouri-Shirazi M, Banchereau J, Bell D, Burkeholder S, Kraus ET, Davoust J, et al. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses. J Immunol 2000; 165:3797 - 803; PMID: 11034385
   PubMed Web of Science ®Google Scholar
• Rolland A, Guyon L, Gill M, Cai YH, Banchereau J, McClain K, et al. Increased blood myeloid dendritic cells and dendritic cell-poietins in Langerhans cell histiocytosis. J Immunol 2005; 174:3067 - 71; PMID: 15728521
   PubMed Web of Science ®Google Scholar
• Chomarat P, Banchereau J, Davoust J, Palucka AK. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol 2000; 1:510 - 4; http://dx.doi.org/10.1038/82763; PMID: 11101873
   PubMed Web of Science ®Google Scholar
• Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005; 5:296 - 306; http://dx.doi.org/10.1038/nri1592; PMID: 15803149
   PubMed Web of Science ®Google Scholar
• Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001; 294:1540 - 3; http://dx.doi.org/10.1126/science.1064890; PMID: 11711679
   PubMed Web of Science ®Google Scholar
• Pulendran B, Palucka K, Banchereau J. Sensing pathogens and tuning immune responses. Science 2001; 293:253 - 6; http://dx.doi.org/10.1126/science.1062060; PMID: 11452116
   PubMed Web of Science ®Google Scholar
• Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:245 - 52; http://dx.doi.org/10.1038/32588; PMID: 9521319
   PubMed Web of Science ®Google Scholar
• Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449:419 - 26; http://dx.doi.org/10.1038/nature06175; PMID: 17898760
   PubMed Web of Science ®Google Scholar
• Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol 2013; 31:563 - 604; http://dx.doi.org/10.1146/annurev-immunol-020711-074950; PMID: 23516985
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12:265 - 77; http://dx.doi.org/10.1038/nrc3258; PMID: 22437871
   PubMed Web of Science ®Google Scholar
• Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003; 21:685 - 711; http://dx.doi.org/10.1146/annurev.immunol.21.120601.141040; PMID: 12615891
   PubMed Web of Science ®Google Scholar
• Idoyaga J, Fiorese C, Zbytnuik L, Lubkin A, Miller J, Malissen B, et al. Specialized role of migratory dendritic cells in peripheral tolerance induction. J Clin Invest 2013; 123:844 - 54; PMID: 23298832
   PubMed Web of Science ®Google Scholar
• Watkins SK, Hurwitz AA. FOXO3: A master switch for regulating tolerance and immunity in dendritic cells. Oncoimmunology 2012; 1:252 - 4; http://dx.doi.org/10.4161/onci.1.2.18241; PMID: 22720261
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Kepp O, Kroemer G. Mitochondria: master regulators of danger signalling. Nat Rev Mol Cell Biol 2012; 13:780 - 8; http://dx.doi.org/10.1038/nrm3479; PMID: 23175281
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31:51 - 72; http://dx.doi.org/10.1146/annurev-immunol-032712-100008; PMID: 23157435
   PubMed Web of Science ®Google Scholar
• Cirone M, Di Renzo L, Lotti LV, Conte V, Trivedi P, Santarelli R, et al. Activation of dendritic cells by tumor cell death. Oncoimmunology 2012; 1:1218 - 9; http://dx.doi.org/10.4161/onci.20428; PMID: 23170286
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Vacchelli E, Eggermont A, Fridman WH, Galon J, et al. Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology 2012; 1:1111 - 34; http://dx.doi.org/10.4161/onci.21494; PMID: 23170259
   PubMed Web of Science ®Google Scholar
• Jin P, Han TH, Ren J, Saunders S, Wang E, Marincola FM, et al. Molecular signatures of maturing dendritic cells: implications for testing the quality of dendritic cell therapies. J Transl Med 2010; 8:4; http://dx.doi.org/10.1186/1479-5876-8-4; PMID: 20078880
   PubMed Web of Science ®Google Scholar
• Quah BJ, O’Neill HC. Maturation of function in dendritic cells for tolerance and immunity. J Cell Mol Med 2005; 9:643 - 54; http://dx.doi.org/10.1111/j.1582-4934.2005.tb00494.x; PMID: 16202211
   PubMed Web of Science ®Google Scholar
• Nakahara T, Moroi Y, Uchi H, Furue M. Differential role of MAPK signaling in human dendritic cell maturation and Th1/Th2 engagement. J Dermatol Sci 2006; 42:1 - 11; http://dx.doi.org/10.1016/j.jdermsci.2005.11.004; PMID: 16352421
   PubMed Web of Science ®Google Scholar
• Hammer GE, Ma A. Molecular control of steady-state dendritic cell maturation and immune homeostasis. Annu Rev Immunol 2013; 31:743 - 91; http://dx.doi.org/10.1146/annurev-immunol-020711-074929; PMID: 23330953
   PubMed Web of Science ®Google Scholar
• Reis e Sousa C. Dendritic cells in a mature age. Nat Rev Immunol 2006; 6:476 - 83; http://dx.doi.org/10.1038/nri1845; PMID: 16691244
   PubMed Web of Science ®Google Scholar
• Steinman RM. Decisions about dendritic cells: past, present, and future. Annu Rev Immunol 2012; 30:1 - 22; http://dx.doi.org/10.1146/annurev-immunol-100311-102839; PMID: 22136168
   PubMed Web of Science ®Google Scholar
• Maldonado-López R, De Smedt T, Michel P, Godfroid J, Pajak B, Heirman C, et al. CD8alpha+ and CD8alpha- subclasses of dendritic cells direct the development of distinct T helper cells in vivo. J Exp Med 1999; 189:587 - 92; http://dx.doi.org/10.1084/jem.189.3.587; PMID: 9927520
   PubMed Web of Science ®Google Scholar
• Pulendran B, Smith JL, Caspary G, Brasel K, Pettit D, Maraskovsky E, et al. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc Natl Acad Sci U S A 1999; 96:1036 - 41; http://dx.doi.org/10.1073/pnas.96.3.1036; PMID: 9927689
   PubMed Web of Science ®Google Scholar
• Dudziak D, Kamphorst AO, Heidkamp GF, Buchholz VR, Trumpfheller C, Yamazaki S, et al. Differential antigen processing by dendritic cell subsets in vivo. Science 2007; 315:107 - 11; http://dx.doi.org/10.1126/science.1136080; PMID: 17204652
   PubMed Web of Science ®Google Scholar
• Ueno H, Palucka AK, Banchereau J. The expanding family of dendritic cell subsets. Nat Biotechnol 2010; 28:813 - 5; http://dx.doi.org/10.1038/nbt0810-813; PMID: 20697407
   PubMed Web of Science ®Google Scholar
• Ueno H, Schmitt N, Klechevsky E, Pedroza-Gonzalez A, Matsui T, Zurawski G, et al. Harnessing human dendritic cell subsets for medicine. Immunol Rev 2010; 234:199 - 212; http://dx.doi.org/10.1111/j.0105-2896.2009.00884.x; PMID: 20193020
   PubMed Web of Science ®Google Scholar
• Satpathy AT, Wu X, Albring JC, Murphy KM. Re(de)fining the dendritic cell lineage. Nat Immunol 2012; 13:1145 - 54; http://dx.doi.org/10.1038/ni.2467; PMID: 23160217
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J. Human dendritic cell subsets in vaccination. Curr Opin Immunol 2013; 25:396 - 402; http://dx.doi.org/10.1016/j.coi.2013.05.001; PMID: 23725656
   PubMed Web of Science ®Google Scholar
• Klechevsky E, Banchereau J. Human dendritic cells subsets as targets and vectors for therapy. Ann N Y Acad Sci 2013; 1284:24 - 30; http://dx.doi.org/10.1111/nyas.12113; PMID: 23651190
   PubMed Web of Science ®Google Scholar
• Klechevsky E, Morita R, Liu M, Cao Y, Coquery S, Thompson-Snipes L, et al. Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity 2008; 29:497 - 510; http://dx.doi.org/10.1016/j.immuni.2008.07.013; PMID: 18789730
   PubMed Web of Science ®Google Scholar
• Bachem A, Güttler S, Hartung E, Ebstein F, Schaefer M, Tannert A, et al. Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells. J Exp Med 2010; 207:1273 - 81; http://dx.doi.org/10.1084/jem.20100348; PMID: 20479115
   PubMed Web of Science ®Google Scholar
• Crozat K, Guiton R, Contreras V, Feuillet V, Dutertre CA, Ventre E, et al. The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8alpha+ dendritic cells. J Exp Med 2010; 207:1283 - 92; http://dx.doi.org/10.1084/jem.20100223; PMID: 20479118
   PubMed Web of Science ®Google Scholar
• Jongbloed SL, Kassianos AJ, McDonald KJ, Clark GJ, Ju X, Angel CE, et al. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med 2010; 207:1247 - 60; http://dx.doi.org/10.1084/jem.20092140; PMID: 20479116
   PubMed Web of Science ®Google Scholar
• Poulin LF, Salio M, Griessinger E, Anjos-Afonso F, Craciun L, Chen JL, et al. Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J Exp Med 2010; 207:1261 - 71; http://dx.doi.org/10.1084/jem.20092618; PMID: 20479117
   PubMed Web of Science ®Google Scholar
• Joffre OP, Segura E, Savina A, Amigorena S. Cross-presentation by dendritic cells. Nat Rev Immunol 2012; 12:557 - 69; http://dx.doi.org/10.1038/nri3254; PMID: 22790179
   PubMed Web of Science ®Google Scholar
• Shortman K, Heath WR. The CD8+ dendritic cell subset. Immunol Rev 2010; 234:18 - 31; http://dx.doi.org/10.1111/j.0105-2896.2009.00870.x; PMID: 20193009
   PubMed Web of Science ®Google Scholar
• Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S, et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999; 284:1835 - 7; http://dx.doi.org/10.1126/science.284.5421.1835; PMID: 10364556
   PubMed Web of Science ®Google Scholar
• Cella M, Facchetti F, Lanzavecchia A, Colonna M. Plasmacytoid dendritic cells activated by influenza virus and CD40L drive a potent TH1 polarization. Nat Immunol 2000; 1:305 - 10; http://dx.doi.org/10.1038/79747; PMID: 11017101
   PubMed Web of Science ®Google Scholar
• Gilliet M, Boonstra A, Paturel C, Antonenko S, Xu XL, Trinchieri G, et al. The development of murine plasmacytoid dendritic cell precursors is differentially regulated by FLT3-ligand and granulocyte/macrophage colony-stimulating factor. J Exp Med 2002; 195:953 - 8; http://dx.doi.org/10.1084/jem.20020045; PMID: 11927638
   PubMed Web of Science ®Google Scholar
• Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, Bazan F, et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 2001; 194:863 - 9; http://dx.doi.org/10.1084/jem.194.6.863; PMID: 11561001
   PubMed Web of Science ®Google Scholar
• Gibson SJ, Lindh JM, Riter TR, Gleason RM, Rogers LM, Fuller AE, et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol 2002; 218:74 - 86; http://dx.doi.org/10.1016/S0008-8749(02)00517-8; PMID: 12470615
   PubMed Web of Science ®Google Scholar
• Kadowaki N, Liu YJ. Natural type I interferon-producing cells as a link between innate and adaptive immunity. Hum Immunol 2002; 63:1126 - 32; http://dx.doi.org/10.1016/S0198-8859(02)00751-6; PMID: 12480256
   PubMed Web of Science ®Google Scholar
• Hambleton S, Salem S, Bustamante J, Bigley V, Boisson-Dupuis S, Azevedo J, et al. IRF8 mutations and human dendritic-cell immunodeficiency. N Engl J Med 2011; 365:127 - 38; http://dx.doi.org/10.1056/NEJMoa1100066; PMID: 21524210
   PubMed Web of Science ®Google Scholar
• Lambrecht BN, Hammad H. Taking our breath away: dendritic cells in the pathogenesis of asthma. Nat Rev Immunol 2003; 3:994 - 1003; http://dx.doi.org/10.1038/nri1249; PMID: 14647481
   PubMed Web of Science ®Google Scholar
• Miller E, Bhardwaj N. Dendritic cell dysregulation during HIV-1 infection. Immunol Rev 2013; 254:170 - 89; http://dx.doi.org/10.1111/imr.12082; PMID: 23772620
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006; 6:715 - 27; http://dx.doi.org/10.1038/nri1936; PMID: 16977338
   PubMed Web of Science ®Google Scholar
• Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 2011; 331:1565 - 70; http://dx.doi.org/10.1126/science.1203486; PMID: 21436444
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11:215 - 33; http://dx.doi.org/10.1038/nrd3626; PMID: 22301798
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of anticancer agents: Reinstating immunosurveillance. Immunity 2013; Forthcoming http://dx.doi.org/10.1016/j.immuni.2013.06.014
   Web of Science ®Google Scholar
• Scarlett UK, Rutkowski MR, Rauwerdink AM, Fields J, Escovar-Fadul X, Baird J, et al. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J Exp Med 2012; 209:495 - 506; http://dx.doi.org/10.1084/jem.20111413; PMID: 22351930
   PubMed Web of Science ®Google Scholar
• Tomihara K, Guo M, Shin T, Sun X, Ludwig SM, Brumlik MJ, et al. Antigen-specific immunity and cross-priming by epithelial ovarian carcinoma-induced CD11b(+)Gr-1(+) cells. J Immunol 2010; 184:6151 - 60; http://dx.doi.org/10.4049/jimmunol.0903519; PMID: 20427766
   PubMed Web of Science ®Google Scholar
• Chaput N, Conforti R, Viaud S, Spatz A, Zitvogel L. The Janus face of dendritic cells in cancer. Oncogene 2008; 27:5920 - 31; http://dx.doi.org/10.1038/onc.2008.270; PMID: 18836473
   PubMed Web of Science ®Google Scholar
• Taieb J, Chaput N, Ménard C, Apetoh L, Ullrich E, Bonmort M, et al. A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med 2006; 12:214 - 9; http://dx.doi.org/10.1038/nm1356; PMID: 16444265
   PubMed Web of Science ®Google Scholar
• Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 2013; 38:729 - 41; http://dx.doi.org/10.1016/j.immuni.2013.03.003; PMID: 23562161
   PubMed Web of Science ®Google Scholar
• Senovilla L, Vitale I, Martins I, Tailler M, Pailleret C, Michaud M, et al. An immunosurveillance mechanism controls cancer cell ploidy. Science 2012; 337:1678 - 84; http://dx.doi.org/10.1126/science.1224922; PMID: 23019653
   PubMed Web of Science ®Google Scholar
• Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011; 334:1573 - 7; http://dx.doi.org/10.1126/science.1208347; PMID: 22174255
   PubMed Web of Science ®Google Scholar
• Noessner E, Brech D, Mendler AN, Masouris I, Schlenker R, Prinz PU. Intratumoral alterations of dendritic-cell differentiation and CD8(+) T-cell anergy are immune escape mechanisms of clear cell renal cell carcinoma. Oncoimmunology 2012; 1:1451 - 3; http://dx.doi.org/10.4161/onci.21356; PMID: 23243626
   PubMed Web of Science ®Google Scholar
• Sisirak V, Faget J, Vey N, Blay JY, Ménétrier-Caux C, Caux C, et al. Plasmacytoid dendritic cells deficient in IFNα production promote the amplification of FOXP3(+) regulatory T cells and are associated with poor prognosis in breast cancer patients. Oncoimmunology 2013; 2:e22338; http://dx.doi.org/10.4161/onci.22338; PMID: 23482834
   PubMedGoogle Scholar
• Reichert TE, Scheuer C, Day R, Wagner W, Whiteside TL. The number of intratumoral dendritic cells and zeta-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma. Cancer 2001; 91:2136 - 47; http://dx.doi.org/10.1002/1097-0142(20010601)91:11<2136::AID-CNCR1242>3.0.CO;2-Q; PMID: 11391595
   PubMed Web of Science ®Google Scholar
• Ikeguchi M, Ikeda M, Tatebe S, Maeta M, Kaibara N. Clinical significance of dendritic cell infiltration in esophageal squamous cell carcinoma. Oncol Rep 1998; 5:1185 - 9; PMID: 9683832
   PubMed Web of Science ®Google Scholar
• Ishigami S, Natsugoe S, Matsumoto M, Okumura H, Sakita H, Nakashima S, et al. Clinical implications of intratumoral dendritic cell infiltration in esophageal squamous cell carcinoma. Oncol Rep 2003; 10:1237 - 40; PMID: 12883687
   PubMed Web of Science ®Google Scholar
• Kakeji Y, Maehara Y, Korenaga D, Tsujitani S, Haraguchi M, Watanabe A, et al. Prognostic significance of tumor-host interaction in clinical gastric cancer: relationship between DNA ploidy and dendritic cell infiltration. J Surg Oncol 1993; 52:207 - 12; http://dx.doi.org/10.1002/jso.2930520402; PMID: 8468980
   PubMed Web of Science ®Google Scholar
• Ishigami S, Aikou T, Natsugoe S, Hokita S, Iwashige H, Tokushige M, et al. Prognostic value of HLA-DR expression and dendritic cell infiltration in gastric cancer. Oncology 1998; 55:65 - 9; http://dx.doi.org/10.1159/000011837; PMID: 9428378
   PubMed Web of Science ®Google Scholar
• Okuyama T, Maehara Y, Kakeji Y, Tsuijitani S, Korenaga D, Sugimachi K. Interrelation between tumor-associated cell surface glycoprotein and host immune response in gastric carcinoma patients. Cancer 1998; 82:1468 - 75; http://dx.doi.org/10.1002/(SICI)1097-0142(19980415)82:8<1468::AID-CNCR6>3.0.CO;2-5; PMID: 9554522
   PubMed Web of Science ®Google Scholar
• Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Xiangming C, Iwashige H, et al. Clinical impact of intratumoral natural killer cell and dendritic cell infiltration in gastric cancer. Cancer Lett 2000; 159:103 - 8; http://dx.doi.org/10.1016/S0304-3835(00)00542-5; PMID: 10974412
   PubMed Web of Science ®Google Scholar
• Saito H, Osaki T, Murakami D, Sakamoto T, Kanaji S, Ohro S, et al. Prediction of sites of recurrence in gastric carcinoma using immunohistochemical parameters. J Surg Oncol 2007; 95:123 - 8; http://dx.doi.org/10.1002/jso.20612; PMID: 17262742
   PubMed Web of Science ®Google Scholar
• Daud AI, Mirza N, Lenox B, Andrews S, Urbas P, Gao GX, et al. Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor. J Clin Oncol 2008; 26:3235 - 41; http://dx.doi.org/10.1200/JCO.2007.13.9048; PMID: 18591558
   PubMed Web of Science ®Google Scholar
• Cai XY, Gao Q, Qiu SJ, Ye SL, Wu ZQ, Fan J, et al. Dendritic cell infiltration and prognosis of human hepatocellular carcinoma. J Cancer Res Clin Oncol 2006; 132:293 - 301; http://dx.doi.org/10.1007/s00432-006-0075-y; PMID: 16421755
   PubMed Web of Science ®Google Scholar
• Yin XY, Lu MD, Lai YR, Liang LJ, Huang JF. Prognostic significances of tumor-infiltrating S-100 positive dendritic cells and lymphocytes in patients with hepatocellular carcinoma. Hepatogastroenterology 2003; 50:1281 - 4; PMID: 14571719
   PubMed Web of Science ®Google Scholar
• Nakakubo Y, Miyamoto M, Cho Y, Hida Y, Oshikiri T, Suzuoki M, et al. Clinical significance of immune cell infiltration within gallbladder cancer. Br J Cancer 2003; 89:1736 - 42; http://dx.doi.org/10.1038/sj.bjc.6601331; PMID: 14583778
   PubMed Web of Science ®Google Scholar
• Honig A, Schaller N, Dietl J, Backe J, Kammerer U. S100 as an immunohistochemically-detected marker with prognostic significance in endometrial carcinoma. Anticancer Res 2005; 25:3A 1747 - 53; PMID: 16033094
   PubMed Web of Science ®Google Scholar
• Chang KC, Huang GC, Jones D, Lin YH. Distribution patterns of dendritic cells and T cells in diffuse large B-cell lymphomas correlate with prognoses. Clin Cancer Res 2007; 13:6666 - 72; http://dx.doi.org/10.1158/1078-0432.CCR-07-0504; PMID: 18006767
   PubMed Web of Science ®Google Scholar
• Furihata M, Ohtsuki Y, Sonobe H, Araki K, Ogata T, Toki T, et al. Prognostic significance of simultaneous infiltration of HLA-DR-positive dendritic cells and tumor infiltrating lymphocytes into human esophageal carcinoma. Tohoku J Exp Med 1993; 169:187 - 95; http://dx.doi.org/10.1620/tjem.169.187; PMID: 8248911
   PubMed Web of Science ®Google Scholar
• Iwamoto M, Shinohara H, Miyamoto A, Okuzawa M, Mabuchi H, Nohara T, et al. Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas. Int J Cancer 2003; 104:92 - 7; http://dx.doi.org/10.1002/ijc.10915; PMID: 12532424
   PubMed Web of Science ®Google Scholar
• Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008; 26:4410 - 7; http://dx.doi.org/10.1200/JCO.2007.15.0284; PMID: 18802153
   PubMed Web of Science ®Google Scholar
• Sautès-Fridman C, Cherfils-Vicini J, Damotte D, Fisson S, Fridman WH, Cremer I, et al. Tumor microenvironment is multifaceted. Cancer Metastasis Rev 2011; 30:13 - 25; http://dx.doi.org/10.1007/s10555-011-9279-y; PMID: 21271351
   PubMed Web of Science ®Google Scholar
• Ladányi A, Kiss J, Somlai B, Gilde K, Fejos Z, Mohos A, et al. Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother 2007; 56:1459 - 69; http://dx.doi.org/10.1007/s00262-007-0286-3; PMID: 17279413
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Suzuki K, Yashi M, Yuzawa M, Takayashiki N, Morita T. Tumor infiltrating dendritic cells predict treatment response to immmunotherapy in patients with metastatic renal cell carcinoma. Anticancer Res 2007; 27:1137 - 41; PMID: 17465253
   PubMed Web of Science ®Google Scholar
• Conrad C, Gilliet M. Plasmacytoid dendritic cells and regulatory T cells in the tumor microenvironment: A dangerous liaison. Oncoimmunology 2013; 2:e23887; http://dx.doi.org/10.4161/onci.23887; PMID: 23762788
   PubMed Web of Science ®Google Scholar
• Ishigami S, Ueno S, Matsumoto M, Okumura H, Arigami T, Uchikado Y, et al. Prognostic value of CD208-positive cell infiltration in gastric cancer. Cancer Immunol Immunother 2010; 59:389 - 95; http://dx.doi.org/10.1007/s00262-009-0758-8; PMID: 19760221
   PubMed Web of Science ®Google Scholar
• Sandel MH, Dadabayev AR, Menon AG, Morreau H, Melief CJ, Offringa R, et al. Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization. Clin Cancer Res 2005; 11:2576 - 82; http://dx.doi.org/10.1158/1078-0432.CCR-04-1448; PMID: 15814636
   PubMed Web of Science ®Google Scholar
• Treilleux I, Blay JY, Bendriss-Vermare N, Ray-Coquard I, Bachelot T, Guastalla JP, et al. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res 2004; 10:7466 - 74; http://dx.doi.org/10.1158/1078-0432.CCR-04-0684; PMID: 15569976
   PubMed Web of Science ®Google Scholar
• Jensen TO, Schmidt H, Møller HJ, Donskov F, Høyer M, Sjoegren P, et al. Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma. Cancer 2012; 118:2476 - 85; http://dx.doi.org/10.1002/cncr.26511; PMID: 21953023
   PubMed Web of Science ®Google Scholar
• Labidi-Galy SI, Treilleux I, Goddard-Leon S, Combes JD, Blay JY, Ray-Coquard I, et al. Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis. Oncoimmunology 2012; 1:380 - 2; http://dx.doi.org/10.4161/onci.18801; PMID: 22737622
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Kroemer G. Targeting dendritic cell metabolism in cancer. Nat Med 2010; 16:858 - 9; http://dx.doi.org/10.1038/nm0810-858; PMID: 20689548
   PubMed Web of Science ®Google Scholar
• Kreutz M, Tacken PJ, Figdor CG. Targeting dendritic cells--why bother?. Blood 2013; 121:2836 - 44; http://dx.doi.org/10.1182/blood-2012-09-452078; PMID: 23390195
   PubMed Web of Science ®Google Scholar
• Garcia F, Climent N, Guardo AC, Gil C, Leon A, Autran B, et al. A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication. Sci Transl Med 2013; 5:166ra2.
   Google Scholar
• Lombardi V, Akbari O. Dendritic cell modulation as a new interventional approach for the treatment of asthma. Drug News Perspect 2009; 22:445 - 51; PMID: 20016853
   PubMed Web of Science ®Google Scholar
• Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses. Science 2004; 305:200 - 5; http://dx.doi.org/10.1126/science.1100369; PMID: 15247469
   PubMed Web of Science ®Google Scholar
• Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med 2004; 10:475 - 80; http://dx.doi.org/10.1038/nm1039; PMID: 15122249
   PubMed Web of Science ®Google Scholar
• Nabel GJ. Designing tomorrow’s vaccines. N Engl J Med 2013; 368:551 - 60; http://dx.doi.org/10.1056/NEJMra1204186; PMID: 23388006
   PubMed Web of Science ®Google Scholar
• Gross CC, Wiendl H. Dendritic cell vaccination in autoimmune disease. Curr Opin Rheumatol 2013; 25:268 - 74; http://dx.doi.org/10.1097/BOR.0b013e32835cb9f2; PMID: 23370378
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al, IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411 - 22; http://dx.doi.org/10.1056/NEJMoa1001294; PMID: 20818862
   PubMed Web of Science ®Google Scholar
• Higano CS, Small EJ, Schellhammer P, Yasothan U, Gubernick S, Kirkpatrick P, et al. Sipuleucel-T. Nat Rev Drug Discov 2010; 9:513 - 4; http://dx.doi.org/10.1038/nrd3220; PMID: 20592741
   PubMed Web of Science ®Google Scholar
• Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res 2011; 17:3520 - 6; http://dx.doi.org/10.1158/1078-0432.CCR-10-3126; PMID: 21471425
   PubMed Web of Science ®Google Scholar
• Satoh Y, Esche C, Gambotto A, Shurin GV, Yurkovetsky ZR, Robbins PD, et al. Local administration of IL-12-transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in mice. J Exp Ther Oncol 2002; 2:337 - 49; http://dx.doi.org/10.1046/j.1359-4117.2002.01050.x; PMID: 12440225
   PubMedGoogle Scholar
• Nishioka Y, Hirao M, Robbins PD, Lotze MT, Tahara H. Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res 1999; 59:4035 - 41; PMID: 10463604
   PubMed Web of Science ®Google Scholar
• Yang SC, Hillinger S, Riedl K, Zhang L, Zhu L, Huang M, et al. Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Clin Cancer Res 2004; 10:2891 - 901; http://dx.doi.org/10.1158/1078-0432.CCR-03-0380; PMID: 15102698
   PubMed Web of Science ®Google Scholar
• Hu J, Yuan X, Belladonna ML, Ong JM, Wachsmann-Hogiu S, Farkas DL, et al. Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells. Cancer Res 2006; 66:8887 - 96; http://dx.doi.org/10.1158/0008-5472.CAN-05-3448; PMID: 16951206
   PubMed Web of Science ®Google Scholar
• Endo H, Saito T, Kenjo A, Hoshino M, Terashima M, Sato T, et al. Phase I trial of preoperative intratumoral injection of immature dendritic cells and OK-432 for resectable pancreatic cancer patients. J Hepatobiliary Pancreat Sci 2012; 19:465 - 75; http://dx.doi.org/10.1007/s00534-011-0457-7; PMID: 21983893
   PubMed Web of Science ®Google Scholar
• You CX, Shi M, Liu Y, Cao M, Luo R, Hermonat PL. AAV2/IL-12 gene delivery into dendritic cells (DC) enhances CTL stimulation above other IL-12 applications: Evidence for IL-12 intracrine activity in DC. Oncoimmunology 2012; 1:847 - 55; http://dx.doi.org/10.4161/onci.20504; PMID: 23162752
   PubMed Web of Science ®Google Scholar
• Bol KF, Tel J, de Vries IJ, Figdor CG. Naturally circulating dendritic cells to vaccinate cancer patients. Oncoimmunology 2013; 2:e23431; http://dx.doi.org/10.4161/onci.23431; PMID: 23802086
   PubMedGoogle Scholar
• Nair SK, Snyder D, Rouse BT, Gilboa E. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int J Cancer 1997; 70:706 - 15; http://dx.doi.org/10.1002/(SICI)1097-0215(19970317)70:6<706::AID-IJC13>3.0.CO;2-7; PMID: 9096653
   PubMed Web of Science ®Google Scholar
• DeMatos P, Abdel-Wahab Z, Vervaert C, Hester D, Seigler H. Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice. J Surg Oncol 1998; 68:79 - 91; http://dx.doi.org/10.1002/(SICI)1096-9098(199806)68:2<79::AID-JSO3>3.0.CO;2-H; PMID: 9624036
   PubMed Web of Science ®Google Scholar
• DeMatos P, Abdel-Wahab Z, Vervaert C, Seigler HF. Vaccination with dendritic cells inhibits the growth of hepatic metastases in B6 mice. Cell Immunol 1998; 185:65 - 74; http://dx.doi.org/10.1006/cimm.1998.1277; PMID: 9636684
   PubMed Web of Science ®Google Scholar
• Fields RC, Shimizu K, Mulé JJ. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci U S A 1998; 95:9482 - 7; http://dx.doi.org/10.1073/pnas.95.16.9482; PMID: 9689106
   PubMed Web of Science ®Google Scholar
• Chen Z, Moyana T, Saxena A, Warrington R, Jia Z, Xiang J. Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells. Int J Cancer 2001; 93:539 - 48; http://dx.doi.org/10.1002/ijc.1365; PMID: 11477558
   PubMed Web of Science ®Google Scholar
• Paczesny S, Beranger S, Salzmann JL, Klatzmann D, Colombo BM. Protection of mice against leukemia after vaccination with bone marrow-derived dendritic cells loaded with apoptotic leukemia cells. Cancer Res 2001; 61:2386 - 9; PMID: 11289101
   PubMed Web of Science ®Google Scholar
• Kokhaei P, Choudhury A, Mahdian R, Lundin J, Moshfegh A, Osterborg A, et al. Apoptotic tumor cells are superior to tumor cell lysate, and tumor cell RNA in induction of autologous T cell response in B-CLL. Leukemia 2004; 18:1810 - 5; http://dx.doi.org/10.1038/sj.leu.2403517; PMID: 15385926
   PubMed Web of Science ®Google Scholar
• Kokhaei P, Rezvany MR, Virving L, Choudhury A, Rabbani H, Osterborg A, et al. Dendritic cells loaded with apoptotic tumour cells induce a stronger T-cell response than dendritic cell-tumour hybrids in B-CLL. Leukemia 2003; 17:894 - 9; http://dx.doi.org/10.1038/sj.leu.2402913; PMID: 12750703
   PubMed Web of Science ®Google Scholar
• Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998; 392:86 - 9; http://dx.doi.org/10.1038/32183; PMID: 9510252
   PubMed Web of Science ®Google Scholar
• Albert ML, Pearce SF, Francisco LM, Sauter B, Roy P, Silverstein RL, et al. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 1998; 188:1359 - 68; http://dx.doi.org/10.1084/jem.188.7.1359; PMID: 9763615
   PubMed Web of Science ®Google Scholar
• Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995; 1:1297 - 302; http://dx.doi.org/10.1038/nm1295-1297; PMID: 7489412
   PubMed Web of Science ®Google Scholar
• Ossevoort MA, Feltkamp MC, van Veen KJ, Melief CJ, Kast WM. Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor. J Immunother Emphasis Tumor Immunol 1995; 18:86 - 94; http://dx.doi.org/10.1097/00002371-199508000-00002; PMID: 8574470
   PubMed Web of Science ®Google Scholar
• Mayordomo JI, Loftus DJ, Sakamoto H, De Cesare CM, Appasamy PM, Lotze MT, et al. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med 1996; 183:1357 - 65; http://dx.doi.org/10.1084/jem.183.4.1357; PMID: 8666894
   PubMed Web of Science ®Google Scholar
• Paglia P, Chiodoni C, Rodolfo M, Colombo MP. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 1996; 183:317 - 22; http://dx.doi.org/10.1084/jem.183.1.317; PMID: 8551239
   PubMed Web of Science ®Google Scholar
• Mackey MF, Gunn JR, Maliszewsky C, Kikutani H, Noelle RJ, Barth RJ Jr.. Dendritic cells require maturation via CD40 to generate protective antitumor immunity. J Immunol 1998; 161:2094 - 8; PMID: 9725199
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996; 183:87 - 97; http://dx.doi.org/10.1084/jem.183.1.87; PMID: 8551248
   PubMed Web of Science ®Google Scholar
• Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Garcia-Prats MD, DeLeo AB, et al. Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines. Stem Cells 1997; 15:94 - 103; http://dx.doi.org/10.1002/stem.150094; PMID: 9090785
   PubMed Web of Science ®Google Scholar
• Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, et al. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 1999; 5:405 - 11; http://dx.doi.org/10.1038/7403; PMID: 10202929
   PubMed Web of Science ®Google Scholar
• Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996; 184:465 - 72; http://dx.doi.org/10.1084/jem.184.2.465; PMID: 8760800
   PubMed Web of Science ®Google Scholar
• Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilboa E. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 1997; 186:1177 - 82; http://dx.doi.org/10.1084/jem.186.7.1177; PMID: 9314567
   PubMed Web of Science ®Google Scholar
• Boczkowski D, Nair SK, Nam JH, Lyerly HK, Gilboa E. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res 2000; 60:1028 - 34; PMID: 10706120
   PubMed Web of Science ®Google Scholar
• Irvine AS, Trinder PK, Laughton DL, Ketteringham H, McDermott RH, Reid SC, et al. Efficient nonviral transfection of dendritic cells and their use for in vivo immunization. Nat Biotechnol 2000; 18:1273 - 8; http://dx.doi.org/10.1038/82383; PMID: 11101806
   PubMed Web of Science ®Google Scholar
• Manickan E, Kanangat S, Rouse RJ, Yu Z, Rouse BT. Enhancement of immune response to naked DNA vaccine by immunization with transfected dendritic cells. J Leukoc Biol 1997; 61:125 - 32; PMID: 9021916
   PubMed Web of Science ®Google Scholar
• Song W, Kong HL, Carpenter H, Torii H, Granstein R, Rafii S, et al. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med 1997; 186:1247 - 56; http://dx.doi.org/10.1084/jem.186.8.1247; PMID: 9334364
   PubMed Web of Science ®Google Scholar
• Tüting T, DeLeo AB, Lotze MT, Storkus WJ. Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or “self” antigens induce antitumor immunity in vivo. Eur J Immunol 1997; 27:2702 - 7; http://dx.doi.org/10.1002/eji.1830271033; PMID: 9368629
   PubMed Web of Science ®Google Scholar
• Wan Y, Bramson J, Carter R, Graham F, Gauldie J. Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination. Hum Gene Ther 1997; 8:1355 - 63; http://dx.doi.org/10.1089/hum.1997.8.11-1355; PMID: 9295130
   PubMed Web of Science ®Google Scholar
• McArthur JG, Mulligan RC. Induction of protective anti-tumor immunity by gene-modified dendritic cells. J Immunother 1998; 21:41 - 7; http://dx.doi.org/10.1097/00002371-199801000-00005; PMID: 9456435
   PubMed Web of Science ®Google Scholar
• Ishida T, Chada S, Stipanov M, Nadaf S, Ciernik FI, Gabrilovich DI, et al. Dendritic cells transduced with wild-type p53 gene elicit potent anti-tumour immune responses. Clin Exp Immunol 1999; 117:244 - 51; http://dx.doi.org/10.1046/j.1365-2249.1999.00913.x; PMID: 10444254
   PubMed Web of Science ®Google Scholar
• Tüting T, Steitz J, Brück J, Gambotto A, Steinbrink K, DeLeo AB, et al. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity. J Gene Med 1999; 1:400 - 6; http://dx.doi.org/10.1002/(SICI)1521-2254(199911/12)1:6<400::AID-JGM68>3.0.CO;2-D; PMID: 10753065
   PubMed Web of Science ®Google Scholar
• Wan Y, Emtage P, Zhu Q, Foley R, Pilon A, Roberts B, et al. Enhanced immune response to the melanoma antigen gp100 using recombinant adenovirus-transduced dendritic cells. Cell Immunol 1999; 198:131 - 8; http://dx.doi.org/10.1006/cimm.1999.1585; PMID: 10648127
   PubMed Web of Science ®Google Scholar
• Klein C, Bueler H, Mulligan RC. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. J Exp Med 2000; 191:1699 - 708; http://dx.doi.org/10.1084/jem.191.10.1699; PMID: 10811863
   PubMed Web of Science ®Google Scholar
• Ribas A, Butterfield LH, Hu B, Dissette VB, Chen AY, Koh A, et al. Generation of T-cell immunity to a murine melanoma using MART-1-engineered dendritic cells. J Immunother 2000; 23:59 - 66; http://dx.doi.org/10.1097/00002371-200001000-00008; PMID: 10687138
   PubMed Web of Science ®Google Scholar
• Okada N, Saito T, Masunaga Y, Tsukada Y, Nakagawa S, Mizuguchi H, et al. Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells. Cancer Res 2001; 61:7913 - 9; PMID: 11691812
   PubMed Web of Science ®Google Scholar
• Koido S, Kashiwaba M, Chen D, Gendler S, Kufe D, Gong J. Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA. J Immunol 2000; 165:5713 - 9; PMID: 11067929
   PubMed Web of Science ®Google Scholar
• Nair SK, Heiser A, Boczkowski D, Majumdar A, Naoe M, Lebkowski JS, et al. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 2000; 6:1011 - 7; http://dx.doi.org/10.1038/79519; PMID: 10973321
   PubMed Web of Science ®Google Scholar
• Yamanaka R, Zullo SA, Tanaka R, Blaese M, Xanthopoulos KG. Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semliki forest virus-mediated complementary DNA. J Neurosurg 2001; 94:474 - 81; http://dx.doi.org/10.3171/jns.2001.94.3.0474; PMID: 11235953
   PubMed Web of Science ®Google Scholar
• Insug O, Ku G, Ertl HC, Blaszczyk-Thurin M. A dendritic cell vaccine induces protective immunity to intracranial growth of glioma. Anticancer Res 2002; 22:2A 613 - 21; PMID: 12014629
   PubMed Web of Science ®Google Scholar
• Van Meirvenne S, Straetman L, Heirman C, Dullaers M, De Greef C, Van Tendeloo V, et al. Efficient genetic modification of murine dendritic cells by electroporation with mRNA. Cancer Gene Ther 2002; 9:787 - 97; http://dx.doi.org/10.1038/sj.cgt.7700499; PMID: 12189529
   PubMed Web of Science ®Google Scholar
• Li M, You S, Ge W, Ma S, Ma N, Zhao C. Induction of T-cell immunity against leukemia by dendritic cells pulsed with total RNA isolated from leukemia cells. Chin Med J (Engl) 2003; 116:1655 - 61; PMID: 14642130
   PubMed Web of Science ®Google Scholar
• Minami T, Nakanishi Y, Izumi M, Harada T, Hara N. Enhancement of antigen-presenting capacity and antitumor immunity of dendritic cells pulsed with autologous tumor-derived RNA in mice. J Immunother 2003; 26:420 - 31; http://dx.doi.org/10.1097/00002371-200309000-00005; PMID: 12973031
   PubMed Web of Science ®Google Scholar
• Schmidt T, Ziske C, Märten A, Endres S, Tiemann K, Schmitz V, et al. Intratumoral immunization with tumor RNA-pulsed dendritic cells confers antitumor immunity in a C57BL/6 pancreatic murine tumor model. Cancer Res 2003; 63:8962 - 7; PMID: 14695214
   PubMed Web of Science ®Google Scholar
• Jung CW, Kwon JH, Seol JG, Park WH, Hyun JM, Kim ES, et al. Induction of cytotoxic T lymphocytes by dendritic cells pulsed with murine leukemic cell RNA. Am J Hematol 2004; 75:121 - 7; http://dx.doi.org/10.1002/ajh.10471; PMID: 14978690
   PubMed Web of Science ®Google Scholar
• Liu BY, Chen XH, Gu QL, Li JF, Yin HR, Zhu ZG, et al. Antitumor effects of vaccine consisting of dendritic cells pulsed with tumor RNA from gastric cancer. World J Gastroenterol 2004; 10:630 - 3; PMID: 14991927
   PubMed Web of Science ®Google Scholar
• Zeis M, Siegel S, Wagner A, Schmitz M, Marget M, Kühl-Burmeister R, et al. Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells. J Immunol 2003; 170:5391 - 7; PMID: 12759413
   PubMed Web of Science ®Google Scholar
• Celluzzi CM, Falo LD Jr.. Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. J Immunol 1998; 160:3081 - 5; PMID: 9531260
   PubMed Web of Science ®Google Scholar
• Wang J, Saffold S, Cao X, Krauss J, Chen W. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J Immunol 1998; 161:5516 - 24; PMID: 9820528
   PubMed Web of Science ®Google Scholar
• Tanaka H, Shimizu K, Hayashi T, Shu S. Therapeutic immune response induced by electrofusion of dendritic and tumor cells. Cell Immunol 2002; 220:1 - 12; http://dx.doi.org/10.1016/S0008-8749(03)00009-1; PMID: 12718934
   PubMed Web of Science ®Google Scholar
• Orentas RJ, Schauer D, Bin Q, Johnson BD. Electrofusion of a weakly immunogenic neuroblastoma with dendritic cells produces a tumor vaccine. Cell Immunol 2001; 213:4 - 13; http://dx.doi.org/10.1006/cimm.2001.1864; PMID: 11747351
   PubMed Web of Science ®Google Scholar
• Kjaergaard J, Shimizu K, Shu S. Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine. Cell Immunol 2003; 225:65 - 74; http://dx.doi.org/10.1016/j.cellimm.2003.09.005; PMID: 14698141
   PubMed Web of Science ®Google Scholar
• Sukhorukov VL, Reuss R, Endter JM, Fehrmann S, Katsen-Globa A, Gessner P, et al. A biophysical approach to the optimisation of dendritic-tumour cell electrofusion. Biochem Biophys Res Commun 2006; 346:829 - 39; http://dx.doi.org/10.1016/j.bbrc.2006.05.193; PMID: 16780801
   PubMed Web of Science ®Google Scholar
• Cathelin D, Nicolas A, Bouchot A, Fraszczak J, Labbé J, Bonnotte B. Dendritic cell-tumor cell hybrids and immunotherapy: what’s next?. Cytotherapy 2011; 13:774 - 85; http://dx.doi.org/10.3109/14653249.2011.553593; PMID: 21299362
   PubMed Web of Science ®Google Scholar
• Errington F, Jones J, Merrick A, Bateman A, Harrington K, Gough M, et al. Fusogenic membrane glycoprotein-mediated tumour cell fusion activates human dendritic cells for enhanced IL-12 production and T-cell priming. Gene Ther 2006; 13:138 - 49; http://dx.doi.org/10.1038/sj.gt.3302609; PMID: 16136162
   PubMed Web of Science ®Google Scholar
• Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii S, Soares H, et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 2004; 199:815 - 24; http://dx.doi.org/10.1084/jem.20032220; PMID: 15024047
   PubMed Web of Science ®Google Scholar
• Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med 2002; 196:1627 - 38; http://dx.doi.org/10.1084/jem.20021598; PMID: 12486105
   PubMed Web of Science ®Google Scholar
• Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001; 194:769 - 79; http://dx.doi.org/10.1084/jem.194.6.769; PMID: 11560993
   PubMed Web of Science ®Google Scholar
• Adotevi O, Vingert B, Freyburger L, Shrikant P, Lone YC, Quintin-Colonna F, et al. B subunit of Shiga toxin-based vaccines synergize with alpha-galactosylceramide to break tolerance against self antigen and elicit antiviral immunity. J Immunol 2007; 179:3371 - 9; PMID: 17709554
   PubMed Web of Science ®Google Scholar
• Berraondo P, Nouzé C, Préville X, Ladant D, Leclerc C. Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system. Cancer Res 2007; 67:8847 - 55; http://dx.doi.org/10.1158/0008-5472.CAN-07-0321; PMID: 17875726
   PubMed Web of Science ®Google Scholar
• Tacken PJ, de Vries IJ, Gijzen K, Joosten B, Wu D, Rother RP, et al. Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood 2005; 106:1278 - 85; http://dx.doi.org/10.1182/blood-2005-01-0318; PMID: 15878980
   PubMed Web of Science ®Google Scholar
• Cruz LJ, Tacken PJ, Pots JM, Torensma R, Buschow SI, Figdor CG. Comparison of antibodies and carbohydrates to target vaccines to human dendritic cells via DC-SIGN. Biomaterials 2012; 33:4229 - 39; http://dx.doi.org/10.1016/j.biomaterials.2012.02.036; PMID: 22410170
   PubMed Web of Science ®Google Scholar
• Schreibelt G, Klinkenberg LJ, Cruz LJ, Tacken PJ, Tel J, Kreutz M, et al. The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells. Blood 2012; 119:2284 - 92; http://dx.doi.org/10.1182/blood-2011-08-373944; PMID: 22234694
   PubMed Web of Science ®Google Scholar
• Tacken PJ, Ginter W, Berod L, Cruz LJ, Joosten B, Sparwasser T, et al. Targeting DC-SIGN via its neck region leads to prolonged antigen residence in early endosomes, delayed lysosomal degradation, and cross-presentation. Blood 2011; 118:4111 - 9; http://dx.doi.org/10.1182/blood-2011-04-346957; PMID: 21860028
   PubMed Web of Science ®Google Scholar
• Tacken PJ, Ter Huurne M, Torensma R, Figdor CG. Antibodies and carbohydrate ligands binding to DC-SIGN differentially modulate receptor trafficking. Eur J Immunol 2012; 42:1989 - 98; http://dx.doi.org/10.1002/eji.201142258; PMID: 22653683
   PubMed Web of Science ®Google Scholar
• Tacken PJ, Zeelenberg IS, Cruz LJ, van Hout-Kuijer MA, van de Glind G, Fokkink RG, et al. Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity. Blood 2011; 118:6836 - 44; http://dx.doi.org/10.1182/blood-2011-07-367615; PMID: 21967977
   PubMed Web of Science ®Google Scholar
• Wang B. Targeting dendritic cells in situ for breast cancer immunotherapy. Oncoimmunology 2012; 1:1398 - 400; http://dx.doi.org/10.4161/onci.20982; PMID: 23243606
   PubMed Web of Science ®Google Scholar
• García-Vallejo JJ, Unger WW, Kalay H, van Kooyk Y. Glycan-based DC-SIGN targeting to enhance antigen cross-presentation in anticancer vaccines. Oncoimmunology 2013; 2:e23040; http://dx.doi.org/10.4161/onci.23040; PMID: 23525136
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med 1998; 4:594 - 600; http://dx.doi.org/10.1038/nm0598-594; PMID: 9585234
   PubMed Web of Science ®Google Scholar
• Théry C, Regnault A, Garin J, Wolfers J, Zitvogel L, Ricciardi-Castagnoli P, et al. Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73. J Cell Biol 1999; 147:599 - 610; http://dx.doi.org/10.1083/jcb.147.3.599; PMID: 10545503
   PubMed Web of Science ®Google Scholar
• Viaud S, Théry C, Ploix S, Tursz T, Lapierre V, Lantz O, et al. Dendritic cell-derived exosomes for cancer immunotherapy: what’s next?. Cancer Res 2010; 70:1281 - 5; http://dx.doi.org/10.1158/0008-5472.CAN-09-3276; PMID: 20145139
   PubMed Web of Science ®Google Scholar
• Munich S, Sobo-Vujanovic A, Buchser WJ, Beer-Stolz D, Vujanovic NL. Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands. Oncoimmunology 2012; 1:1074 - 83; http://dx.doi.org/10.4161/onci.20897; PMID: 23170255
   PubMed Web of Science ®Google Scholar
• Kandalaft LE, Powell DJ Jr., Chiang CL, Tanyi J, Kim S, Bosch M, et al. Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. Oncoimmunology 2013; 2:e22664; http://dx.doi.org/10.4161/onci.22664; PMID: 23482679
   PubMed Web of Science ®Google Scholar
• Fučíková J, Rožková D, Ulčová H, Budinský V, Sochorová K, Pokorná K, et al. Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials. J Transl Med 2011; 9:223; http://dx.doi.org/10.1186/1479-5876-9-223; PMID: 22208910
   PubMed Web of Science ®Google Scholar
• Fucikova J, Kralikova P, Fialova A, Brtnicky T, Rob L, Bartunkova J, et al. Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res 2011; 71:4821 - 33; http://dx.doi.org/10.1158/0008-5472.CAN-11-0950; PMID: 21602432
   PubMed Web of Science ®Google Scholar
• Bercovici N, Haicheur N, Massicard S, Vernel-Pauillac F, Adotevi O, Landais D, et al. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients. J Immunother 2008; 31:101 - 12; http://dx.doi.org/10.1097/CJI.0b013e318159f5ba; PMID: 18157017
   PubMed Web of Science ®Google Scholar
• Lee J, Boczkowski D, Nair S. Programming human dendritic cells with mRNA. Methods Mol Biol 2013; 969:111 - 25; http://dx.doi.org/10.1007/978-1-62703-260-5_8; PMID: 23296931
   PubMedGoogle Scholar
• Blalock LT, Landsberg J, Messmer M, Shi J, Pardee AD, Haskell R, et al. Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity. Oncoimmunology 2012; 1:287 - 357; http://dx.doi.org/10.4161/onci.18628; PMID: 22737604
   PubMed Web of Science ®Google Scholar
• Koido S, Homma S, Okamoto M, Namiki Y, Takakura K, Uchiyama K, et al. Fusions between dendritic cells and whole tumor cells as anticancer vaccines. Oncoimmunology 2013; 2:e24437; http://dx.doi.org/10.4161/onci.24437; PMID: 23762810
   PubMedGoogle Scholar
• Copland MJ, Baird MA, Rades T, McKenzie JL, Becker B, Reck F, et al. Liposomal delivery of antigen to human dendritic cells. Vaccine 2003; 21:883 - 90; http://dx.doi.org/10.1016/S0264-410X(02)00536-4; PMID: 12547598
   PubMed Web of Science ®Google Scholar
• van Broekhoven CL, Parish CR, Demangel C, Britton WJ, Altin JG. Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy. Cancer Res 2004; 64:4357 - 65; http://dx.doi.org/10.1158/0008-5472.CAN-04-0138; PMID: 15205352
   PubMed Web of Science ®Google Scholar
• Badiee A, Davies N, McDonald K, Radford K, Michiue H, Hart D, et al. Enhanced delivery of immunoliposomes to human dendritic cells by targeting the multilectin receptor DEC-205. Vaccine 2007; 25:4757 - 66; http://dx.doi.org/10.1016/j.vaccine.2007.04.029; PMID: 17512099
   PubMed Web of Science ®Google Scholar
• Gilboa E. DC-based cancer vaccines. J Clin Invest 2007; 117:1195 - 203; http://dx.doi.org/10.1172/JCI31205; PMID: 17476349
   PubMed Web of Science ®Google Scholar
• Tacken PJ, de Vries IJ, Torensma R, Figdor CG. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 2007; 7:790 - 802; http://dx.doi.org/10.1038/nri2173; PMID: 17853902
   PubMed Web of Science ®Google Scholar
• Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev Immunol 2003; 3:630 - 41; http://dx.doi.org/10.1038/nri1150; PMID: 12974478
   PubMed Web of Science ®Google Scholar
• Finn OJ. Cancer immunology. N Engl J Med 2008; 358:2704 - 15; http://dx.doi.org/10.1056/NEJMra072739; PMID: 18565863
   PubMed Web of Science ®Google Scholar
• Scanlon CS, D’Silva NJ. Personalized medicine for cancer therapy: Lessons learned from tumor-associated antigens. Oncoimmunology 2013; 2:e23433; http://dx.doi.org/10.4161/onci.23433; PMID: 23734304
   PubMedGoogle Scholar
• Li Y, Cozzi PJ, Russell PJ. Promising tumor-associated antigens for future prostate cancer therapy. Med Res Rev 2010; 30:67 - 101; PMID: 19536865
   PubMed Web of Science ®Google Scholar
• Buonaguro L, Petrizzo A, Tornesello ML, Buonaguro FM. Translating tumor antigens into cancer vaccines. Clin Vaccine Immunol 2011; 18:23 - 34; http://dx.doi.org/10.1128/CVI.00286-10; PMID: 21048000
   PubMed Web of Science ®Google Scholar
• Farkas AM, Finn OJ. Vaccines based on abnormal self-antigens as tumor-associated antigens: immune regulation. Semin Immunol 2010; 22:125 - 31; http://dx.doi.org/10.1016/j.smim.2010.03.003; PMID: 20403708
   PubMed Web of Science ®Google Scholar
• Mocellin S, Pilati P, Nitti D. Peptide-based anticancer vaccines: recent advances and future perspectives. Curr Med Chem 2009; 16:4779 - 96; http://dx.doi.org/10.2174/092986709789909648; PMID: 19929787
   PubMed Web of Science ®Google Scholar
• Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15:5323 - 37; http://dx.doi.org/10.1158/1078-0432.CCR-09-0737; PMID: 19723653
   PubMed Web of Science ®Google Scholar
• Cavallo F, Calogero RA, Forni G. Are oncoantigens suitable targets for anti-tumour therapy?. Nat Rev Cancer 2007; 7:707 - 13; http://dx.doi.org/10.1038/nrc2208; PMID: 17700704
   PubMed Web of Science ®Google Scholar
• Amos SM, Duong CP, Westwood JA, Ritchie DS, Junghans RP, Darcy PK, et al. Autoimmunity associated with immunotherapy of cancer. Blood 2011; 118:499 - 509; http://dx.doi.org/10.1182/blood-2011-01-325266; PMID: 21531979
   PubMed Web of Science ®Google Scholar
• Caspi RR. Immunotherapy of autoimmunity and cancer: the penalty for success. Nat Rev Immunol 2008; 8:970 - 6; http://dx.doi.org/10.1038/nri2438; PMID: 19008897
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Wolchok JD. Is tumor immunity the same thing as autoimmunity? Implications for cancer immunotherapy. J Clin Oncol 2006; 24:2230 - 2; http://dx.doi.org/10.1200/JCO.2006.05.6952; PMID: 16710020
   PubMed Web of Science ®Google Scholar
• Koon H, Atkins M. Autoimmunity and immunotherapy for cancer. N Engl J Med 2006; 354:758 - 60; http://dx.doi.org/10.1056/NEJMe058307; PMID: 16481646
   PubMed Web of Science ®Google Scholar
• Overwijk WW, Restifo NP. Autoimmunity and the immunotherapy of cancer: targeting the “self” to destroy the “other”. Crit Rev Immunol 2000; 20:433 - 50; http://dx.doi.org/10.1615/CritRevImmunol.v20.i6.10; PMID: 11396680
   PubMed Web of Science ®Google Scholar
• Kroemer G, Zitvogel L. Can the exome and the immunome converge on the design of efficient cancer vaccines?. Oncoimmunology 2012; 1:579 - 80; http://dx.doi.org/10.4161/onci.20730; PMID: 22934249
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Eggermont A, Sautes-Fridman C, Galon J, Zitvogel L, Kroemer G, et al. Trial Watch: Toll-like receptor agonists for cancer therapy. OncoImmunology 2013; 2; Forthcoming PMID: 23162757
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Martins I, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, et al. Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology 2012; 1:1557 - 76; http://dx.doi.org/10.4161/onci.22428; PMID: 23264902
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Galluzzi L, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, et al. Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012; 1:894 - 907; http://dx.doi.org/10.4161/onci.20931; PMID: 23162757
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, et al. Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012; 1:699 - 716; http://dx.doi.org/10.4161/onci.20696; PMID: 22934262
   PubMed Web of Science ®Google Scholar
• Wathelet N, Moser M. Role of dendritic cells in the regulation of antitumor immunity. Oncoimmunology 2013; 2:e23973; http://dx.doi.org/10.4161/onci.23973; PMID: 23734333
   PubMedGoogle Scholar
• Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, et al. Trial Watch: Adoptive cell transfer immunotherapy. Oncoimmunology 2012; 1:306 - 15; http://dx.doi.org/10.4161/onci.19549; PMID: 22737606
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vacchelli E, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, et al. Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology 2012; 1:28 - 37; http://dx.doi.org/10.4161/onci.1.1.17938; PMID: 22720209
   PubMed Web of Science ®Google Scholar
• Menger L, Vacchelli E, Kepp O, Eggermont A, Tartour E, Zitvogel L, et al. Trial watch: Cardiac glycosides and cancer therapy. Oncoimmunology 2013; 2:e23082; http://dx.doi.org/10.4161/onci.23082; PMID: 23525565
   PubMed Web of Science ®Google Scholar
• Senovilla L, Vacchelli E, Galon J, Adjemian S, Eggermont A, Fridman WH, et al. Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology 2012; 1:1323 - 43; http://dx.doi.org/10.4161/onci.22009; PMID: 23243596
   PubMed Web of Science ®Google Scholar
• Senovilla L, Vacchelli E, Garcia P, Eggermont A, Fridman WH, Galon J, et al. Trial watch: DNA vaccines for cancer therapy. Oncoimmunology 2013; 2:e23803; http://dx.doi.org/10.4161/onci.23803; PMID: 23734328
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Eggermont A, Fridman WH, Galon J, Tartour E, Zitvogel L, et al. Trial Watch: Adoptive cell transfer for anticancer immunotherapy. Oncoimmunology 2013; 2:e24238; http://dx.doi.org/10.4161/onci.24238; PMID: 23762803
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, et al. Trial Watch: Immunostimulatory cytokines. OncoImmunology 2013; 2:e24850; PMID: 22754768
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Eggermont A, Galon J, Sautès-Fridman C, Zitvogel L, Kroemer G, et al. Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology 2013; 2:e22789; http://dx.doi.org/10.4161/onci.22789; PMID: 23482847
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, et al. Trial Watch: Oncolytic viruses for cancer therapy. OncoImmunology 2013; 2:e24612; http://dx.doi.org/10.4161/onci.24612
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Galluzzi L, Eggermont A, Galon J, Tartour E, Zitvogel L, et al. Trial Watch: Immunostimulatory cytokines. Oncoimmunology 2012; 1:493 - 506; http://dx.doi.org/10.4161/onci.20459; PMID: 22754768
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Galluzzi L, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, et al. Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2012; 1:179 - 88; http://dx.doi.org/10.4161/onci.1.2.19026; PMID: 22720239
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Senovilla L, Eggermont A, Fridman WH, Galon J, Zitvogel L, et al. Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2013; 2:e23510; http://dx.doi.org/10.4161/onci.23510; PMID: 23687621
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Vitale I, Tartour E, Eggermont A, Sautes-Fridman C, Galon J, et al. Trial Watch: Anticancer radioimmunotherapy. OncoImmunology 2013; 2:e25595; http://dx.doi.org/10.4161/onci.24238
   PubMed Web of Science ®Google Scholar
• Iwami K, Shimato S, Ohno M, Okada H, Nakahara N, Sato Y, et al. Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor α2 chain in recurrent malignant glioma patients with HLA-A*24/A*02 allele. Cytotherapy 2012; 14:733 - 42; PMID: 22424217
   PubMed Web of Science ®Google Scholar
• Akiyama Y, Oshita C, Kume A, Iizuka A, Miyata H, Komiyama M, et al. α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial. BMC Cancer 2012; 12:623; http://dx.doi.org/10.1186/1471-2407-12-623; PMID: 23270484
   PubMed Web of Science ®Google Scholar
• Phuphanich S, Wheeler CJ, Rudnick JD, Mazer M, Wang H, Nuño MA, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother 2013; 62:125 - 35; http://dx.doi.org/10.1007/s00262-012-1319-0; PMID: 22847020
   PubMed Web of Science ®Google Scholar
• Fong B, Jin R, Wang X, Safaee M, Lisiero DN, Yang I, et al. Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients. PLoS One 2012; 7:e32614; http://dx.doi.org/10.1371/journal.pone.0032614; PMID: 22485134
   PubMed Web of Science ®Google Scholar
• Zahradova L, Mollova K, Ocadlikova D, Kovarova L, Adam Z, Krejci M, et al. Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma--phase II study results. Neoplasma 2012; 59:440 - 9; http://dx.doi.org/10.4149/neo_2012_057; PMID: 22489700
   PubMed Web of Science ®Google Scholar
• Aarntzen EH, De Vries IJ, Lesterhuis WJ, Schuurhuis D, Jacobs JF, Bol K, et al. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res 2013; 73:19 - 29; http://dx.doi.org/10.1158/0008-5472.CAN-12-1127; PMID: 23087058
   PubMed Web of Science ®Google Scholar
• Tel J, Aarntzen EH, Baba T, Schreibelt G, Schulte BM, Benitez-Ribas D, et al. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res 2013; 73:1063 - 75; http://dx.doi.org/10.1158/0008-5472.CAN-12-2583; PMID: 23345163
   PubMed Web of Science ®Google Scholar
• Oshita C, Takikawa M, Kume A, Miyata H, Ashizawa T, Iizuka A, et al. Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial. Oncol Rep 2012; 28:1131 - 8; PMID: 22895835
   PubMed Web of Science ®Google Scholar
• Sharma A, Koldovsky U, Xu S, Mick R, Roses R, Fitzpatrick E, et al. HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. Cancer 2012; 118:4354 - 62; http://dx.doi.org/10.1002/cncr.26734; PMID: 22252842
   PubMed Web of Science ®Google Scholar
• Tada F, Abe M, Hirooka M, Ikeda Y, Hiasa Y, Lee Y, et al. Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma. Int J Oncol 2012; 41:1601 - 9; PMID: 22971679
   PubMed Web of Science ®Google Scholar
• Cho DY, Yang WK, Lee HC, Hsu DM, Lin HL, Lin SZ, et al. Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trial. World Neurosurg 2012; 77:736 - 44; http://dx.doi.org/10.1016/j.wneu.2011.08.020; PMID: 22120301
   PubMed Web of Science ®Google Scholar
• Himoudi N, Wallace R, Parsley KL, Gilmour K, Barrie AU, Howe K, et al. Lack of T-cell responses following autologous tumour lysate pulsed dendritic cell vaccination, in patients with relapsed osteosarcoma. Clin Transl Oncol 2012; 14:271 - 9; http://dx.doi.org/10.1007/s12094-012-0795-1; PMID: 22484634
   PubMed Web of Science ®Google Scholar
• Florcken A, Kopp J, van Lessen A, Movassaghi K, Takvorian A, Johrens K, et al. Allogeneic partially HLA-matched dendritic cells pulsed with autologous tumor cell lysate as a vaccine in metastatic renal cell cancer: A clinical phase I/II study. Hum Vaccin Immunother 2013; 9:9; http://dx.doi.org/10.4161/hv.24149; PMID: 23570049
   PubMed Web of Science ®Google Scholar
• Kamigaki T, Kaneko T, Naitoh K, Takahara M, Kondo T, Ibe H, et al. Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors. Anticancer Res 2013; 33:2971 - 6; PMID: 23780988
   PubMed Web of Science ®Google Scholar
• Chia WK, Wang WW, Teo M, Tai WM, Lim WT, Tan EH, et al. A phase II study evaluating the safety and efficacy of an adenovirus-ΔLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma. Ann Oncol 2012; 23:997 - 1005; http://dx.doi.org/10.1093/annonc/mdr341; PMID: 21821548
   PubMed Web of Science ®Google Scholar
• Van Nuffel AM, Benteyn D, Wilgenhof S, Corthals J, Heirman C, Neyns B, et al. Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient. Cancer Immunol Immunother 2012; 61:1033 - 43; http://dx.doi.org/10.1007/s00262-011-1176-2; PMID: 22159452
   PubMed Web of Science ®Google Scholar
• Iclozan C, Antonia S, Chiappori A, Chen DT, Gabrilovich D. Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol Immunother 2013; 62:909 - 18; http://dx.doi.org/10.1007/s00262-013-1396-8; PMID: 23589106
   PubMed Web of Science ®Google Scholar
• Morse MA, Niedzwiecki D, Marshall JL, Garrett C, Chang DZ, Aklilu M, et al. A randomized Phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. Ann Surg 2013; http://dx.doi.org/10.1097/SLA.0b013e318292919e; PMID: 23657083
   PubMed Web of Science ®Google Scholar
• Ardon H, Van Gool SW, Verschuere T, Maes W, Fieuws S, Sciot R, et al. Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial. Cancer Immunol Immunother 2012; 61:2033 - 44; http://dx.doi.org/10.1007/s00262-012-1261-1; PMID: 22527250
   PubMed Web of Science ®Google Scholar
• Hunn MK, Hermans IF. Exploiting invariant NKT cells to promote T-cell responses to cancer vaccines. Oncoimmunology 2013; 2:e23789; http://dx.doi.org/10.4161/onci.23789; PMID: 23734325
   PubMedGoogle Scholar
• Mattarollo SR, Smyth MJ. NKT cell adjuvants in therapeutic vaccines against hematological cancers. Oncoimmunology 2013; 2:e22615; http://dx.doi.org/10.4161/onci.22615; PMID: 23482240
   PubMedGoogle Scholar
• Hsu A, Ritchie DS, Neeson P. Are the immuno-stimulatory properties of Lenalidomide extinguished by co-administration of Dexamethasone?. Oncoimmunology 2012; 1:372 - 4; http://dx.doi.org/10.4161/onci.18963; PMID: 22737619
   PubMed Web of Science ®Google Scholar
• Richter J, Neparidze N, Zhang L, Nair S, Monesmith T, Sundaram R, et al. Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma. Blood 2013; 121:423 - 30; http://dx.doi.org/10.1182/blood-2012-06-435503; PMID: 23100308
   PubMed Web of Science ®Google Scholar
• Rosenblatt J, Avivi I, Vasir B, Uhl L, Munshi NC, Katz T, et al. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res 2013; 19:3640 - 8; http://dx.doi.org/10.1158/1078-0432.CCR-13-0282; PMID: 23685836
   PubMed Web of Science ®Google Scholar
• Aarntzen EH, Schreibelt G, Bol K, Lesterhuis WJ, Croockewit AJ, de Wilt JH, et al. Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients. Clin Cancer Res 2012; 18:5460 - 70; http://dx.doi.org/10.1158/1078-0432.CCR-11-3368; PMID: 22896657
   PubMed Web of Science ®Google Scholar
• Le Mercier I, Poujol D, Sanlaville A, Sisirak V, Gobert M, Durand I, et al. Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment. Cancer Res 2013; http://dx.doi.org/10.1158/0008-5472.CAN-12-3058; PMID: 23722543
   PubMed Web of Science ®Google Scholar
• Tel J, Schreibelt G, Sittig SP, Mathan TS, Buschow SI, Cruz LJ, et al. Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell subsets. Blood 2013; 121:459 - 67; http://dx.doi.org/10.1182/blood-2012-06-435644; PMID: 23212525
   PubMed Web of Science ®Google Scholar
• Tel J, Smits EL, Anguille S, Joshi RN, Figdor CG, de Vries IJ. Human plasmacytoid dendritic cells are equipped with antigen-presenting and tumoricidal capacities. Blood 2012; 120:3936 - 44; http://dx.doi.org/10.1182/blood-2012-06-435941; PMID: 22966165
   PubMed Web of Science ®Google Scholar
• Tel J, van der Leun AM, Figdor CG, Torensma R, de Vries IJ. Harnessing human plasmacytoid dendritic cells as professional APCs. Cancer Immunol Immunother 2012; 61:1279 - 88; http://dx.doi.org/10.1007/s00262-012-1210-z; PMID: 22294456
   PubMed Web of Science ®Google Scholar
• Aspord C, Leccia MT, Salameire D, Laurin D, Chaperot L, Charles J, et al. HLA-A(*)0201(+) plasmacytoid dendritic cells provide a cell-based immunotherapy for melanoma patients. J Invest Dermatol 2012; 132:2395 - 406; http://dx.doi.org/10.1038/jid.2012.152; PMID: 22696054
   PubMed Web of Science ®Google Scholar
• Bell BD, Kitajima M, Larson RP, Stoklasek TA, Dang K, Sakamoto K, et al. The transcription factor STAT5 is critical in dendritic cells for the development of TH2 but not TH1 responses. Nat Immunol 2013; 14:364 - 71; http://dx.doi.org/10.1038/ni.2541; PMID: 23435120
   PubMed Web of Science ®Google Scholar
• Segura E, Touzot M, Bohineust A, Cappuccio A, Chiocchia G, Hosmalin A, et al. Human inflammatory dendritic cells induce Th17 cell differentiation. Immunity 2013; 38:336 - 48; http://dx.doi.org/10.1016/j.immuni.2012.10.018; PMID: 23352235
   PubMed Web of Science ®Google Scholar
• Guermonprez P, Helft J, Claser C, Deroubaix S, Karanje H, Gazumyan A, et al. Inflammatory Flt3l is essential to mobilize dendritic cells and for T cell responses during Plasmodium infection. Nat Med 2013; 19:730 - 8; http://dx.doi.org/10.1038/nm.3197; PMID: 23685841
   PubMed Web of Science ®Google Scholar
• Banchereau J, Zurawski S, Thompson-Snipes L, Blanck JP, Clayton S, Munk A, et al. Immunoglobulin-like transcript receptors on human dermal CD14+ dendritic cells act as a CD8-antagonist to control cytotoxic T cell priming. Proc Natl Acad Sci U S A 2012; 109:18885 - 90; http://dx.doi.org/10.1073/pnas.1205785109; PMID: 23112154
   PubMed Web of Science ®Google Scholar
• Schlitzer A, McGovern N, Teo P, Zelante T, Atarashi K, Low D, et al. IRF4 transcription factor-dependent CD11b+ dendritic cells in human and mouse control mucosal IL-17 cytokine responses. Immunity 2013; 38:970 - 83; http://dx.doi.org/10.1016/j.immuni.2013.04.011; PMID: 23706669
   PubMed Web of Science ®Google Scholar
• Wong JL, Berk E, Edwards RP, Kalinski P. IL-18-primed helper NK cells collaborate with dendritic cells to promote recruitment of effector CD8+ T cells to the tumor microenvironment. Cancer Res 2013.
   Google Scholar
• Heesters BA, Chatterjee P, Kim YA, Gonzalez SF, Kuligowski MP, Kirchhausen T, et al. Endocytosis and recycling of immune complexes by follicular dendritic cells enhances B cell antigen binding and activation. Immunity 2013; 38:1164 - 75; http://dx.doi.org/10.1016/j.immuni.2013.02.023; PMID: 23770227
   PubMed Web of Science ®Google Scholar
• Furuta K, Ishido S, Roche PA. Encounter with antigen-specific primed CD4 T cells promotes MHC class II degradation in dendritic cells. Proc Natl Acad Sci U S A 2012; 109:19380 - 5; http://dx.doi.org/10.1073/pnas.1213868109; PMID: 23129633
   PubMed Web of Science ®Google Scholar
• Zhang Z, Bao M, Lu N, Weng L, Yuan B, Liu YJ. The E3 ubiquitin ligase TRIM21 negatively regulates the innate immune response to intracellular double-stranded DNA. Nat Immunol 2013; 14:172 - 8; http://dx.doi.org/10.1038/ni.2492; PMID: 23222971
   PubMed Web of Science ®Google Scholar
• Lutz MB. How quantitative differences in dendritic cell maturation can direct TH1/TH2-cell polarization. Oncoimmunology 2013; 2:e22796; http://dx.doi.org/10.4161/onci.22796; PMID: 23525517
   PubMedGoogle Scholar
• Clausen BE, Girard-Madoux MJ. IL-10 control of dendritic cells in the skin. Oncoimmunology 2013; 2:e23186; http://dx.doi.org/10.4161/onci.23186; PMID: 23802070
   PubMedGoogle Scholar
• Mandaric S, Walton SM, Rülicke T, Richter K, Girard-Madoux MJ, Clausen BE, et al. IL-10 suppression of NK/DC crosstalk leads to poor priming of MCMV-specific CD4 T cells and prolonged MCMV persistence. PLoS Pathog 2012; 8:e1002846; http://dx.doi.org/10.1371/journal.ppat.1002846; PMID: 22876184
   PubMedGoogle Scholar
• Coquet JM, Ribot JC, Bąbała N, Middendorp S, van der Horst G, Xiao Y, et al. Epithelial and dendritic cells in the thymic medulla promote CD4+Foxp3+ regulatory T cell development via the CD27-CD70 pathway. J Exp Med 2013; 210:715 - 28; http://dx.doi.org/10.1084/jem.20112061; PMID: 23547099
   PubMed Web of Science ®Google Scholar
• Volpi C, Fallarino F, Pallotta MT, Bianchi R, Vacca C, Belladonna ML, et al. High doses of CpG oligodeoxynucleotides stimulate a tolerogenic TLR9-TRIF pathway. Nat Commun 2013; 4:1852; http://dx.doi.org/10.1038/ncomms2874; PMID: 23673637
   PubMed Web of Science ®Google Scholar
• Chiba S, Baghdadi M, Akiba H, Yoshiyama H, Kinoshita I, Dosaka-Akita H, et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol 2012; 13:832 - 42; http://dx.doi.org/10.1038/ni.2376; PMID: 22842346
   PubMed Web of Science ®Google Scholar
• Han D, Walsh MC, Cejas PJ, Dang NN, Kim YF, Kim J, et al. Dendritic cell expression of the signaling molecule TRAF6 is critical for gut microbiota-dependent immune tolerance. Immunity 2013; 38:1211 - 22; http://dx.doi.org/10.1016/j.immuni.2013.05.012; PMID: 23791643
   PubMed Web of Science ®Google Scholar
• Jellison ER, Turner MJ, Blair DA, Lingenheld EG, Zu L, Puddington L, et al. Distinct mechanisms mediate naive and memory CD8 T-cell tolerance. Proc Natl Acad Sci U S A 2012; 109:21438 - 43; http://dx.doi.org/10.1073/pnas.1217409110; PMID: 23236165
   PubMed Web of Science ®Google Scholar
• Vitali C, Mingozzi F, Broggi A, Barresi S, Zolezzi F, Bayry J, et al. Migratory, and not lymphoid-resident, dendritic cells maintain peripheral self-tolerance and prevent autoimmunity via induction of iTreg cells. Blood 2012; 120:1237 - 45; http://dx.doi.org/10.1182/blood-2011-09-379776; PMID: 22760781
   PubMed Web of Science ®Google Scholar
• Claus C, Riether C, Schürch C, Matter MS, Hilmenyuk T, Ochsenbein AF. CD27 signaling increases the frequency of regulatory T cells and promotes tumor growth. Cancer Res 2012; 72:3664 - 76; http://dx.doi.org/10.1158/0008-5472.CAN-11-2791; PMID: 22628427
   PubMed Web of Science ®Google Scholar
• Oh J, Wu N, Baravalle G, Cohn B, Ma J, Lo B, et al. MARCH1-mediated MHCII ubiquitination promotes dendritic cell selection of natural regulatory T cells. J Exp Med 2013; 210:1069 - 77; http://dx.doi.org/10.1084/jem.20122695; PMID: 23712430
   PubMed Web of Science ®Google Scholar
• Aguilera-Montilla N, Chamorro S, Nieto C, Sánchez-Cabo F, Dopazo A, Fernández-Salguero PM, et al. Aryl hydrocarbon receptor contributes to the MEK/ERK-dependent maintenance of the immature state of human dendritic cells. Blood 2013; 121:e108 - 17; http://dx.doi.org/10.1182/blood-2012-07-445106; PMID: 23430108
   PubMedGoogle Scholar
• Zietara N, Łyszkiewicz M, Puchałka J, Pei G, Gutierrez MG, Lienenklaus S, et al. Immunoglobulins drive terminal maturation of splenic dendritic cells. Proc Natl Acad Sci U S A 2013; 110:2282 - 7; http://dx.doi.org/10.1073/pnas.1210654110; PMID: 23345431
   PubMed Web of Science ®Google Scholar
• Kim SJ, Gregersen PK, Diamond B. Regulation of dendritic cell activation by microRNA let-7c and BLIMP1. J Clin Invest 2013; 123:823 - 33; PMID: 23298838
   PubMed Web of Science ®Google Scholar
• Wan CK, Oh J, Li P, West EE, Wong EA, Andraski AB, et al. The cytokines IL-21 and GM-CSF have opposing regulatory roles in the apoptosis of conventional dendritic cells. Immunity 2013; 38:514 - 27; http://dx.doi.org/10.1016/j.immuni.2013.02.011; PMID: 23453633
   PubMed Web of Science ®Google Scholar
• Gatto D, Wood K, Caminschi I, Murphy-Durland D, Schofield P, Christ D, et al. The chemotactic receptor EBI2 regulates the homeostasis, localization and immunological function of splenic dendritic cells. Nat Immunol 2013; 14:446 - 53; http://dx.doi.org/10.1038/ni.2555; PMID: 23502855
   PubMed Web of Science ®Google Scholar
• Segura E, Durand M, Amigorena S. Similar antigen cross-presentation capacity and phagocytic functions in all freshly isolated human lymphoid organ-resident dendritic cells. J Exp Med 2013; 210:1035 - 47; http://dx.doi.org/10.1084/jem.20121103; PMID: 23569327
   PubMed Web of Science ®Google Scholar
• Cohn L, Chatterjee B, Esselborn F, Smed-Sörensen A, Nakamura N, Chalouni C, et al. Antigen delivery to early endosomes eliminates the superiority of human blood BDCA3+ dendritic cells at cross presentation. J Exp Med 2013; 210:1049 - 63; http://dx.doi.org/10.1084/jem.20121251; PMID: 23569326
   PubMed Web of Science ®Google Scholar
• Chatterjee B, Smed-Sörensen A, Cohn L, Chalouni C, Vandlen R, Lee BC, et al. Internalization and endosomal degradation of receptor-bound antigens regulate the efficiency of cross presentation by human dendritic cells. Blood 2012; 120:2011 - 20; http://dx.doi.org/10.1182/blood-2012-01-402370; PMID: 22791285
   PubMed Web of Science ®Google Scholar
• Hoffmann E, Kotsias F, Visentin G, Bruhns P, Savina A, Amigorena S. Autonomous phagosomal degradation and antigen presentation in dendritic cells. Proc Natl Acad Sci U S A 2012; 109:14556 - 61; http://dx.doi.org/10.1073/pnas.1203912109; PMID: 22908282
   PubMed Web of Science ®Google Scholar
• Li C, Buckwalter MR, Basu S, Garg M, Chang J, Srivastava PK. Dendritic cells sequester antigenic epitopes for prolonged periods in the absence of antigen-encoding genetic information. Proc Natl Acad Sci U S A 2012; 109:17543 - 8; http://dx.doi.org/10.1073/pnas.1205867109; PMID: 23045695
   PubMed Web of Science ®Google Scholar
• Segura E, Amigorena S. Identification of human inflammatory dendritic cells. Oncoimmunology 2013; 2:e23851; http://dx.doi.org/10.4161/onci.23851; PMID: 23762786
   PubMed Web of Science ®Google Scholar
• Onai N, Kurabayashi K, Hosoi-Amaike M, Toyama-Sorimachi N, Matsushima K, Inaba K, et al. A clonogenic progenitor with prominent plasmacytoid dendritic cell developmental potential. Immunity 2013; 38:943 - 57; http://dx.doi.org/10.1016/j.immuni.2013.04.006; PMID: 23623382
   PubMed Web of Science ®Google Scholar
• Welner RS, Bararia D, Amabile G, Czibere A, Benoukraf T, Bach C, et al. C/EBPα is required for development of dendritic cell progenitors. Blood 2013; 121:4073 - 81; http://dx.doi.org/10.1182/blood-2012-10-463448; PMID: 23547051
   PubMed Web of Science ®Google Scholar
• Naik SH, Perié L, Swart E, Gerlach C, van Rooij N, de Boer RJ, et al. Diverse and heritable lineage imprinting of early haematopoietic progenitors. Nature 2013; 496:229 - 32; http://dx.doi.org/10.1038/nature12013; PMID: 23552896
   PubMed Web of Science ®Google Scholar
• Sathe P, Vremec D, Wu L, Corcoran L, Shortman K. Convergent differentiation: myeloid and lymphoid pathways to murine plasmacytoid dendritic cells. Blood 2013; 121:11 - 9; http://dx.doi.org/10.1182/blood-2012-02-413336; PMID: 23053574
   PubMed Web of Science ®Google Scholar
• Beisner DR, Langerak P, Parker AE, Dahlberg C, Otero FJ, Sutton SE, et al. The intramembrane protease Sppl2a is required for B cell and DC development and survival via cleavage of the invariant chain. J Exp Med 2013; 210:23 - 30; http://dx.doi.org/10.1084/jem.20121072; PMID: 23267013
   PubMed Web of Science ®Google Scholar
• Greter M, Lelios I, Pelczar P, Hoeffel G, Price J, Leboeuf M, et al. Stroma-derived interleukin-34 controls the development and maintenance of langerhans cells and the maintenance of microglia. Immunity 2012; 37:1050 - 60; http://dx.doi.org/10.1016/j.immuni.2012.11.001; PMID: 23177320
   PubMed Web of Science ®Google Scholar
• Bauer T, Zagórska A, Jurkin J, Yasmin N, Köffel R, Richter S, et al. Identification of Axl as a downstream effector of TGF-β1 during Langerhans cell differentiation and epidermal homeostasis. J Exp Med 2012; 209:2033 - 47; http://dx.doi.org/10.1084/jem.20120493; PMID: 23071254
   PubMed Web of Science ®Google Scholar
• Tussiwand R, Lee WL, Murphy TL, Mashayekhi M, Wumesh KC, Albring JC, et al. Compensatory dendritic cell development mediated by BATF-IRF interactions. Nature 2012; 490:502 - 7; http://dx.doi.org/10.1038/nature11531; PMID: 22992524
   PubMed Web of Science ®Google Scholar
• Greter M, Helft J, Chow A, Hashimoto D, Mortha A, Agudo-Cantero J, et al. GM-CSF controls nonlymphoid tissue dendritic cell homeostasis but is dispensable for the differentiation of inflammatory dendritic cells. Immunity 2012; 36:1031 - 46; http://dx.doi.org/10.1016/j.immuni.2012.03.027; PMID: 22749353
   PubMed Web of Science ®Google Scholar
• Wang Y, Szretter KJ, Vermi W, Gilfillan S, Rossini C, Cella M, et al. IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia. Nat Immunol 2012; 13:753 - 60; http://dx.doi.org/10.1038/ni.2360; PMID: 22729249
   PubMed Web of Science ®Google Scholar
• Bergmann H, Yabas M, Short A, Miosge L, Barthel N, Teh CE, et al. B cell survival, surface BCR and BAFFR expression, CD74 metabolism, and CD8- dendritic cells require the intramembrane endopeptidase SPPL2A. J Exp Med 2013; 210:31 - 40; http://dx.doi.org/10.1084/jem.20121076; PMID: 23267016
   PubMed Web of Science ®Google Scholar
• Nizzoli G, Krietsch J, Weick A, Steinfelder S, Facciotti F, Gruarin P, et al. Human CD1c+ dendritic cells secrete high levels of IL-12 and potently prime cytotoxic T cell responses. Blood 2013; http://dx.doi.org/10.1182/blood-2013-04-495424; PMID: 23794066
   PubMed Web of Science ®Google Scholar
• Meixlsperger S, Leung CS, Rämer PC, Pack M, Vanoaica LD, Breton G, et al. CD141+ dendritic cells produce prominent amounts of IFN-α after dsRNA recognition and can be targeted via DEC-205 in humanized mice. Blood 2013; 121:5034 - 44; http://dx.doi.org/10.1182/blood-2012-12-473413; PMID: 23482932
   PubMed Web of Science ®Google Scholar
• Haniffa M, Shin A, Bigley V, McGovern N, Teo P, See P, et al. Human tissues contain CD141hi cross-presenting dendritic cells with functional homology to mouse CD103+ nonlymphoid dendritic cells. Immunity 2012; 37:60 - 73; http://dx.doi.org/10.1016/j.immuni.2012.04.012; PMID: 22795876
   PubMed Web of Science ®Google Scholar
• Meredith MM, Liu K, Darrasse-Jeze G, Kamphorst AO, Schreiber HA, Guermonprez P, et al. Expression of the zinc finger transcription factor zDC (Zbtb46, Btbd4) defines the classical dendritic cell lineage. J Exp Med 2012; 209:1153 - 65; http://dx.doi.org/10.1084/jem.20112675; PMID: 22615130
   PubMed Web of Science ®Google Scholar
• Seré K, Baek JH, Ober-Blöbaum J, Müller-Newen G, Tacke F, Yokota Y, et al. Two distinct types of Langerhans cells populate the skin during steady state and inflammation. Immunity 2012; 37:905 - 16; http://dx.doi.org/10.1016/j.immuni.2012.07.019; PMID: 23159228
   PubMed Web of Science ®Google Scholar
• Poulin LF, Reyal Y, Uronen-Hansson H, Schraml BU, Sancho D, Murphy KM, et al. DNGR-1 is a specific and universal marker of mouse and human Batf3-dependent dendritic cells in lymphoid and nonlymphoid tissues. Blood 2012; 119:6052 - 62; http://dx.doi.org/10.1182/blood-2012-01-406967; PMID: 22442345
   PubMed Web of Science ®Google Scholar
• Roothans D, Smits E, Lion E, Tel J, Anguille S. CD56 marks human dendritic cell subsets with cytotoxic potential. Oncoimmunology 2013; 2:e23037; http://dx.doi.org/10.4161/onci.23037; PMID: 23524451
   PubMedGoogle Scholar
• Lindenberg JJ, van de Ven R, Lougheed SM, Zomer A, Santegoets SJ, Griffioen AW, et al. Functional characterization of a STAT3-dependent dendritic cell-derived CD14(+) cell population arising upon IL-10-driven maturation. Oncoimmunology 2013; 2:e23837; http://dx.doi.org/10.4161/onci.23837; PMID: 23734330
   PubMed Web of Science ®Google Scholar
• Haniffa M, Collin M, Ginhoux F. Identification of human tissue cross-presenting dendritic cells: A new target for cancer vaccines. Oncoimmunology 2013; 2:e23140; http://dx.doi.org/10.4161/onci.23140; PMID: 23802067
   PubMed Web of Science ®Google Scholar
• van de Laar L, van den Bosch A, Boonstra A, Binda RS, Buitenhuis M, Janssen HL, et al. PI3K-PKB hyperactivation augments human plasmacytoid dendritic cell development and function. Blood 2012; 120:4982 - 91; http://dx.doi.org/10.1182/blood-2012-02-413229; PMID: 23091295
   PubMed Web of Science ®Google Scholar
• Weigert A, Weichand B, Sekar D, Sha W, Hahn C, Mora J, et al. HIF-1α is a negative regulator of plasmacytoid DC development in vitro and in vivo. Blood 2012; 120:3001 - 6; http://dx.doi.org/10.1182/blood-2012-03-417022; PMID: 22936665
   PubMed Web of Science ®Google Scholar
• Faget J, Bendriss-Vermare N, Gobert M, Durand I, Olive D, Biota C, et al. ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells. Cancer Res 2012; 72:6130 - 41; http://dx.doi.org/10.1158/0008-5472.CAN-12-2409; PMID: 23026134
   PubMed Web of Science ®Google Scholar
• Conrad C, Gregorio J, Wang YH, Ito T, Meller S, Hanabuchi S, et al. Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3(+) T-regulatory cells. Cancer Res 2012; 72:5240 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-12-2271; PMID: 22850422
   PubMed Web of Science ®Google Scholar
• Sisirak V, Faget J, Gobert M, Goutagny N, Vey N, Treilleux I, et al. Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. Cancer Res 2012; 72:5188 - 97; http://dx.doi.org/10.1158/0008-5472.CAN-11-3468; PMID: 22836755
   PubMed Web of Science ®Google Scholar
• Yu H, Huang X, Liu X, Jin H, Zhang G, Zhang Q, et al. Regulatory T cells and plasmacytoid dendritic cells contribute to the immune escape of papillary thyroid cancer coexisting with multinodular non-toxic goiter. Endocrine 2012; Forthcoming http://dx.doi.org/10.1007/s12020-012-9853-2; PMID: 23264145
   PubMed Web of Science ®Google Scholar
• Sawant A, Ponnazhagan S. Role of plasmacytoid dendritic cells in breast cancer bone dissemination. Oncoimmunology 2013; 2:e22983; http://dx.doi.org/10.4161/onci.22983; PMID: 23526329
   PubMedGoogle Scholar
• Bobr A, Igyarto BZ, Haley KM, Li MO, Flavell RA, Kaplan DH. Autocrine/paracrine TGF-β1 inhibits Langerhans cell migration. Proc Natl Acad Sci U S A 2012; 109:10492 - 7; http://dx.doi.org/10.1073/pnas.1119178109; PMID: 22689996
   PubMed Web of Science ®Google Scholar
• Weber M, Hauschild R, Schwarz J, Moussion C, de Vries I, Legler DF, et al. Interstitial dendritic cell guidance by haptotactic chemokine gradients. Science 2013; 339:328 - 32; http://dx.doi.org/10.1126/science.1228456; PMID: 23329049
   PubMed Web of Science ®Google Scholar
• Lamsoul I, Métais A, Gouot E, Heuzé ML, Lennon-Duménil AM, Moog-Lutz C, et al. ASB2α regulates migration of immature dendritic cells. Blood 2013; Forthcoming http://dx.doi.org/10.1182/blood-2012-11-466649; PMID: 23632887
   PubMed Web of Science ®Google Scholar
• Segura E, Valladeau-Guilemond J, Donnadieu MH, Sastre-Garau X, Soumelis V, Amigorena S. Characterization of resident and migratory dendritic cells in human lymph nodes. J Exp Med 2012; 209:653 - 60; http://dx.doi.org/10.1084/jem.20111457; PMID: 22430490
   PubMed Web of Science ®Google Scholar
• Seré K, Felker P, Hieronymus T, Zenke M. TGFβ1 microenvironment determines dendritic cell development. Oncoimmunology 2013; 2:e23083; http://dx.doi.org/10.4161/onci.23083; PMID: 23687620
   PubMedGoogle Scholar
• Diana J, Simoni Y, Furio L, Beaudoin L, Agerberth B, Barrat F, et al. Crosstalk between neutrophils, B-1a cells and plasmacytoid dendritic cells initiates autoimmune diabetes. Nat Med 2013; 19:65 - 73; http://dx.doi.org/10.1038/nm.3042; PMID: 23242473
   PubMed Web of Science ®Google Scholar
• Frleta D, Ochoa CE, Kramer HB, Khan SA, Stacey AR, Borrow P, et al. HIV-1 infection-induced apoptotic microparticles inhibit human DCs via CD44. J Clin Invest 2012; 122:4685 - 97; http://dx.doi.org/10.1172/JCI64439; PMID: 23160198
   PubMed Web of Science ®Google Scholar
• Prada N, Antoni G, Commo F, Rusakiewicz S, Semeraro M, Boufassa F, et al. Analysis of NKp30/NCR3 isoforms in untreated HIV-1-infected patients from the ANRS SEROCO cohort. Oncoimmunology 2013; 2:e23472; http://dx.doi.org/10.4161/onci.23472; PMID: 23802087
   PubMed Web of Science ®Google Scholar
• Srivastava RM, Lee SC, Andrade Filho PA, Lord CA, Jie HB, Davidson HC, et al. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res 2013; 19:1858 - 72; http://dx.doi.org/10.1158/1078-0432.CCR-12-2426; PMID: 23444227
   PubMed Web of Science ®Google Scholar
• Kang TH, Mao CP, Lee SY, Chen A, Lee JH, Kim TW, et al. Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity. Cancer Res 2013; 73:2493 - 504; http://dx.doi.org/10.1158/0008-5472.CAN-12-4241; PMID: 23418322
   PubMed Web of Science ®Google Scholar
• Munir S, Andersen GH, Met O, Donia M, Frøsig TM, Larsen SK, et al. HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients. Cancer Res 2013; 73:1764 - 76; http://dx.doi.org/10.1158/0008-5472.CAN-12-3507; PMID: 23328583
   PubMed Web of Science ®Google Scholar
• Faget J, Sisirak V, Blay JY, Caux C, Bendriss-Vermare N, Ménétrier-Caux C. ICOS is associated with poor prognosis in breast cancer as it promotes the amplification of immunosuppressive CD4(+) T cells by plasmacytoid dendritic cells. Oncoimmunology 2013; 2:e23185; http://dx.doi.org/10.4161/onci.23185; PMID: 23802069
   PubMed Web of Science ®Google Scholar
• Schreiber TH, Wolf D, Bodero M, Podack E. Tumor antigen specific iTreg accumulate in the tumor microenvironment and suppress therapeutic vaccination. Oncoimmunology 2012; 1:642 - 8; http://dx.doi.org/10.4161/onci.20298; PMID: 22934256
   PubMed Web of Science ®Google Scholar
• Pinto A, Rega A, Crother TR, Sorrentino R. Plasmacytoid dendritic cells and their therapeutic activity in cancer. Oncoimmunology 2012; 1:726 - 34; http://dx.doi.org/10.4161/onci.20171; PMID: 22934264
   PubMed Web of Science ®Google Scholar
• Fonteneau JF, Guillerme JB, Tangy F, Grégoire M. Attenuated measles virus used as an oncolytic virus activates myeloid and plasmacytoid dendritic cells. Oncoimmunology 2013; 2:e24212; http://dx.doi.org/10.4161/onci.24212; PMID: 23762802
   PubMedGoogle Scholar
• van den Loosdrecht AA, Santegoets SJ, van Wetering S, Kaugh Singh S, Koppes M, Hall A, et al. Allogeneic dendritic cell (DC) vaccination as an “off the shelf” treatment to prevent or delay relapse in elderly acute myeloid leukemia patients: Results of phase I study. J Clin Oncol 2013; abstract 3029
   Web of Science ®Google Scholar
• Boehrer S, Adès L, Braun T, Galluzzi L, Grosjean J, Fabre C, et al. Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study. Blood 2008; 111:2170 - 80; http://dx.doi.org/10.1182/blood-2007-07-100362; PMID: 17925489
   PubMed Web of Science ®Google Scholar
• Yang Y, Lizée G, Hwu P. Strong emerging rationale for combining oncogene-targeted agents with immunotherapy. Oncoimmunology 2013; 2:e22730; http://dx.doi.org/10.4161/onci.22730; PMID: 23524978
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Jabbour E, Grimley J, Kirkpatrick P. Dasatinib. Nat Rev Drug Discov 2006; 5:717 - 8; http://dx.doi.org/10.1038/nrd2135; PMID: 17001803
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362:2260 - 70; http://dx.doi.org/10.1056/NEJMoa1002315; PMID: 20525995
   PubMed Web of Science ®Google Scholar
• Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354:2531 - 41; http://dx.doi.org/10.1056/NEJMoa055229; PMID: 16775234
   PubMed Web of Science ®Google Scholar
• Levy HB, Baer G, Baron S, Buckler CE, Gibbs CJ, Iadarola MJ, et al. A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates. J Infect Dis 1975; 132:434 - 9; http://dx.doi.org/10.1093/infdis/132.4.434; PMID: 810520
   PubMed Web of Science ®Google Scholar
• Kroemer G, Zitvogel L. Abscopal but desirable: The contribution of immune responses to the efficacy of radiotherapy. Oncoimmunology 2012; 1:407 - 8; http://dx.doi.org/10.4161/onci.20074; PMID: 22754758
   PubMed Web of Science ®Google Scholar
• Mothersill C, Seymour CB. Radiation-induced bystander effects--implications for cancer. Nat Rev Cancer 2004; 4:158 - 64; http://dx.doi.org/10.1038/nrc1277; PMID: 14964312
   PubMed Web of Science ®Google Scholar
• Prise KM, O’Sullivan JM. Radiation-induced bystander signalling in cancer therapy. Nat Rev Cancer 2009; 9:351 - 60; http://dx.doi.org/10.1038/nrc2603; PMID: 19377507
   PubMed Web of Science ®Google Scholar
• Ribas A, Comin-Anduix B, Chmielowski B, Jalil J, de la Rocha P, McCannel TA, et al. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res 2009; 15:6267 - 76; http://dx.doi.org/10.1158/1078-0432.CCR-09-1254; PMID: 19789309
   PubMed Web of Science ®Google Scholar
• Comin-Anduix B, Sazegar H, Chodon T, Matsunaga D, Jalil J, von Euw E, et al. Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma. PLoS One 2010; 5:e12711; http://dx.doi.org/10.1371/journal.pone.0012711; PMID: 20856802
   PubMedGoogle Scholar
• Zitvogel L, Kroemer G. Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology 2012; 1:1223 - 5; http://dx.doi.org/10.4161/onci.21335; PMID: 23243584
   PubMed Web of Science ®Google Scholar
• Madan RA, Heery CR, Gulley JL. Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity. Oncoimmunology 2012; 1:1167 - 8; http://dx.doi.org/10.4161/onci.20591; PMID: 23170267
   PubMed Web of Science ®Google Scholar
• Lee SK, Surh CD. Role of interleukin-7 in bone and T-cell homeostasis. Immunol Rev 2005; 208:169 - 80; http://dx.doi.org/10.1111/j.0105-2896.2005.00339.x; PMID: 16313348
   PubMed Web of Science ®Google Scholar
• Sportès C, Gress RE, Mackall CL. Perspective on potential clinical applications of recombinant human interleukin-7. Ann N Y Acad Sci 2009; 1182:28 - 38; http://dx.doi.org/10.1111/j.1749-6632.2009.05075.x; PMID: 20074272
   PubMed Web of Science ®Google Scholar
• Simmons SJ, Tjoa BA, Rogers M, Elgamal A, Kenny GM, Ragde H, et al. GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial. Prostate 1999; 39:291 - 7; http://dx.doi.org/10.1002/(SICI)1097-0045(19990601)39:4<291::AID-PROS10>3.0.CO;2-9; PMID: 10344219
   PubMed Web of Science ®Google Scholar
• Alfaro C, Perez-Gracia JL, Suarez N, Rodriguez J, Fernandez de Sanmamed M, Sangro B, et al. Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients. J Immunol 2011; 187:6130 - 42; http://dx.doi.org/10.4049/jimmunol.1102209; PMID: 22048768
   PubMed Web of Science ®Google Scholar
• Kan S, Hazama S, Maeda K, Inoue Y, Homma S, Koido S, et al. Suppressive effects of cyclophosphamide and gemcitabine on regulatory T-cell induction in vitro. Anticancer Res 2012; 32:5363 - 9; PMID: 23225438
   PubMed Web of Science ®Google Scholar
• Tongu M, Harashima N, Monma H, Inao T, Yamada T, Kawauchi H, et al. Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo. Cancer Immunol Immunother 2013; 62:383 - 91; http://dx.doi.org/10.1007/s00262-012-1343-0; PMID: 22926062
   PubMed Web of Science ®Google Scholar
• Holcmann M, Drobits B, Sibilia M. How imiquimod licenses plasmacytoid dendritic cells to kill tumors. Oncoimmunology 2012; 1:1661 - 3; http://dx.doi.org/10.4161/onci.22033; PMID: 23264929
   PubMed Web of Science ®Google Scholar
• Hotz C, Bourquin C. Systemic cancer immunotherapy with Toll-like receptor 7 agonists: Timing is everything. Oncoimmunology 2012; 1:227 - 8; http://dx.doi.org/10.4161/onci.1.2.18169; PMID: 22720251
   PubMed Web of Science ®Google Scholar
• Walter A, Schäfer M, Cecconi V, Matter C, Urosevic-Maiwald M, Belloni B, et al. Aldara activates TLR7-independent immune defence. Nat Commun 2013; 4:1560; http://dx.doi.org/10.1038/ncomms2566; PMID: 23463003
   PubMed Web of Science ®Google Scholar
• Richel O, de Vries HJ, van Noesel CJ, Dijkgraaf MG, Prins JM. Comparison of imiquimod, topical fluorouracil, and electrocautery for the treatment of anal intraepithelial neoplasia in HIV-positive men who have sex with men: an open-label, randomised controlled trial. Lancet Oncol 2013; 14:346 - 53; http://dx.doi.org/10.1016/S1470-2045(13)70067-6; PMID: 23499546
   PubMed Web of Science ®Google Scholar
• Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002; 3:196 - 200; http://dx.doi.org/10.1038/ni758; PMID: 11812998
   PubMed Web of Science ®Google Scholar
• Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24:3089 - 94; http://dx.doi.org/10.1200/JCO.2005.04.5252; PMID: 16809734
   PubMed Web of Science ®Google Scholar
• Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009; 115:3670 - 9; http://dx.doi.org/10.1002/cncr.24429; PMID: 19536890
   PubMed Web of Science ®Google Scholar
• Yamazaki T, Hannani D, Poirier-Colame V, Ladoire S, Locher C, Sistigu A, et al. Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. Cell Death Differ 2013; Forthcoming http://dx.doi.org/10.1038/cdd.2013.72; PMID: 23811849
   PubMed Web of Science ®Google Scholar
• de Vries IJ, Lesterhuis WJ, Scharenborg NM, Engelen LP, Ruiter DJ, Gerritsen MJ, et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 2003; 9:5091 - 100; PMID: 14613986
   PubMed Web of Science ®Google Scholar
• de Vries IJ, Bernsen MR, Lesterhuis WJ, Scharenborg NM, Strijk SP, Gerritsen MJ, et al. Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol 2005; 23:5779 - 87; http://dx.doi.org/10.1200/JCO.2005.06.478; PMID: 16110035
   PubMed Web of Science ®Google Scholar
• Paczesny S, Banchereau J, Wittkowski KM, Saracino G, Fay J, Palucka AK. Expansion of melanoma-specific cytolytic CD8+ T cell precursors in patients with metastatic melanoma vaccinated with CD34+ progenitor-derived dendritic cells. J Exp Med 2004; 199:1503 - 11; http://dx.doi.org/10.1084/jem.20032118; PMID: 15173207
   PubMed Web of Science ®Google Scholar
• Welters MJ, Kenter GG, de Vos van Steenwijk PJ, Löwik MJ, Berends-van der Meer DM, Essahsah F, et al. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci U S A 2010; 107:11895 - 9; http://dx.doi.org/10.1073/pnas.1006500107; PMID: 20547850
   PubMed Web of Science ®Google Scholar